Hydrophilic-group-containing antibody-drug conjugate and use thereof

By designing a novel type of hydrophilic linker, the in vivo stability of ADCs and the aggregation problem caused by hydrophobic payloads were solved, thereby improving the stability and safety of ADCs and enhancing the pharmacokinetics and safety of the drug.

WO2026233201A1PCT designated stage Publication Date: 2026-11-12BEIJING TIDE PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/093885
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-04-29
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing antibody-drug conjugate (ADC) linkers are not stable enough in vivo, leading to premature off-target effects of cytotoxins, which affect efficacy and increase toxicity. Furthermore, hydrophobic payloads lead to aggregation tendency and immunogenicity risks. Existing linkers are also complex to design and manufacture.

Method used

A novel hydrophilic linker with a novel structural type was designed. Glu(E') was used to construct the enzymatic hydrolysis site, and an ethylenediamine (DEA) structure was introduced. The hydrophobicity of the payload was improved through polyhydroxy alcohol modification, thereby increasing plasma stability and optimizing drug release performance.

Benefits of technology

It improves the stability and hydrophilicity of ADCs, enhances drug efficacy, reduces off-target toxicity, and improves the drug properties and safety of the product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026093885_12112026_PF_FP_ABST
    Figure CN2026093885_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A hydrophilic-group-containing antibody-drug conjugate and the use thereof. The present invention specifically relates to a linker as represented by formula (I), which contains a hydrophilic group of a new structural type, a linker-payload conjugate, an antibody-drug conjugate based on the linker and the use thereof, and further relates to a pharmaceutical composition containing the antibody-drug conjugate, and the use of the antibody-drug conjugate in the treatment and / or prevention of diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Antibody-drug conjugates containing hydrophilic groups and their uses

[0001] This application claims priority to Chinese application 2025105790029, filed on May 6, 2025, which is incorporated herein by reference in its entirety. Technical Field

[0002] This invention belongs to the field of medicinal chemistry, specifically relating to a linker containing a hydrophilic group of a novel structural type, a linker-payload, an antibody-drug conjugate (ADC) based on the linker, and the use thereof. It also relates to pharmaceutical compositions containing antibody-drug conjugates, and the use of these antibody-drug conjugates for the treatment and / or prevention of diseases. Background Technology

[0003] Antibody-drug conjugates (ADCs) structurally consist of three parts: a monoclonal antibody, a cytotoxin, and a linker. The antibody targets the target cell, the cytotoxin kills the target cell, and the linker binds the antibody and cytotoxin together structurally, forming a unified whole. The performance of the linker is crucial for ensuring the targeted delivery of the cytotoxin, directly determining the efficacy, safety, and pharmacokinetic characteristics of the ADC. Therefore, the construction of the linker is of great significance to ADC drug development.

[0004] ADCs utilize biologically targeted monoclonal antibodies to deliver potent cytotoxins to the lesion site. They combine the advantages of both antibodies and cytotoxic drugs, and have many benefits such as strong targeting, high activity, low toxicity and side effects, and long half-life.

[0005] Several important factors need to be considered in the development of ADC linkers, including the selection of antibody conjugation sites, the average number of cytotoxic molecules conjugated per antibody molecule (drug / antibody ratio, DAR), linker cleavability, and linker hydrophilicity. The basic requirements for ADC linkers include ensuring stability within the human circulatory system throughout the entire treatment cycle after ADC administration, and the ability to rapidly and effectively release the payload upon reaching the target tissue. Only in this way can the ADC effectively leverage both antibody targeting and high toxicity.

[0006] In addition, the design of the connector needs to match the physicochemical properties of the connected load, thereby adjusting the hydrophilicity of the connector-load combination. Appropriate hydrophilic design of the connector can achieve multiple benefits, including improving the water solubility of the connector-load combination during coupling, increasing coupling yield, reducing the degree of polymerization of the product, improving product stability, and enhancing product bioavailability and pharmacokinetics.

[0007] Therefore, the selection of linkers and conjugation strategies is extremely critical in the design and development of ADC drugs. The linker of an ADC must ensure effective binding between the antibody and the cytotoxin before reaching the target tissue. If the cytotoxin deviates from the target tissue before the ADC reaches it, on the one hand, the decrease in loading rate will greatly reduce the effective loading concentration released by the ADC to the target tissue, thereby reducing the efficacy of the ADC; on the other hand, the detached potent cytotoxin will also cause significant off-target toxicity to normal tissues.

[0008] Currently, among marketed and clinically investigated ADC drugs, the vast majority still employ the Michael addition reaction between thiol and maleimide to generate thiosuccinimide during their construction. Due to the numerous advantages of this reaction, such as its speed, quantification, and mild conditions, no superior alternative has yet been found for its application in current ADC research.

[0009] However, the thiosuccinimide group generated in the ADC product constructed through the above reaction is unstable. After ADC administration, it will continuously undergo a retro-Michael reaction in vivo, resulting in a continuous off-target release of highly potent cytotoxins from the ADC into normal tissues (Figure 1). The maleimide group generated off-target will further react rapidly with substances containing thiol groups in the blood, such as albumin, glutathione, and cysteine, further accelerating the off-target process of cytotoxins from the ADC. According to reports, in in vitro mouse plasma, the off-target amount of cytotoxins from ADC can be as high as 50% within 3 days, while in in vivo mouse models, the off-target amount of cytotoxins can be as high as 60% after one week of ADC administration (Nature Biotech., 2014, 32(10): 1059-1062.). The aforementioned metabolism of ADCs in vivo will undoubtedly lead to a decrease in ADC efficacy and an increase in toxicity (Nature Biotech., 2012, 30(2): 184-189.; Bioconjugate Chem., 2008, 19(3): 759-765.; Bioconjug Chem., 2016, 27(7): 1588-1598.; J Med Chem., 2014, 57(19): 7890-7899.).

[0010] On the other hand, due to the low solubility of small cytotoxic payloads in water, their strong hydrophobicity leads to a tendency for protein aggregation and aggregate formation after conjugation to antibodies. When the number of payloads conjugated per antibody molecule (DAR) is large, the resulting ADC product not only exhibits stronger hydrophobicity and polymerization compared to spiroantibodies, but also shows increased metabolic rate and immunogenicity risk in vivo. Therefore, designing potent hydrophilic groups to modify the linker is beneficial not only for improving the drug-like properties of ADCs, but also for improving the pharmacokinetic properties and drug safety of the product.

[0011] Topoisomerase I inhibitor payloads, represented by ixenolide (Dx-8951f), are currently widely used in ADC research. For example, Innovent Biologics' ADC drug IBI343, targeting CLDN18.2, is currently in Phase III clinical trials. Several other biopharmaceutical companies have also developed multiple ADCs using ixenolide as a payload, demonstrating promising clinical application prospects. However, due to the extremely high hydrophobicity of the ixenolide molecule, the linker it is paired with must contain sufficient hydrophilic modification groups.

[0012] Current mainstream ADC linker technologies cannot adequately ensure the stability of ADCs before reaching the target tissue, and they also suffer from the problems of complex structures and complicated fabrication processes for modified hydrophilic groups. The construction of next-generation linkers has become a crucial issue and significant challenge in ADC development. Besides stability, there is still considerable room for optimization in many aspects of ADCs, including linker drug release performance optimization, hydrophilicity optimization, and the rational combination of linkers and payloads. Summary of the Invention

[0013] Specifically, this invention relates to a linker containing a hydrophilic group of a novel structural type, a linker-payload, an antibody-drug conjugate (ADC) based on the linker, and uses thereof, as well as pharmaceutical compositions containing the antibody-drug conjugate, and uses of these antibody-drug conjugates for the treatment and / or prevention of diseases.

[0014] This application provides an antibody-drug conjugate (ADC), its intermediate, a preparation method, and its application. The ADC of this application enables the widespread use of cytotoxic drugs in the ADC field, primarily for the treatment of tumor diseases. The main technical advantage of this application is that it provides a novel type of hydrophilic group, which, when linked to a linker, effectively enhances the stability and hydrophilicity of the ADC.

[0015] In terms of improving ADC stability, in order to overcome the problem that traditional drug release technology based on Val-Cit cleavage peptides is susceptible to interference from enzymes such as carboxylesterase Ces1C and human neutrophil elastase (NE), which leads to premature linker cleavage and premature payload release and potential off-target toxicity, this invention redesigns the structure of cleavable peptide linkers. Novel E'VA and VE' are constructed using hydrophilically modified Glu(E') as recognition sites for lysosomal proteases. By increasing the steric hindrance near the cleavage sites, the stability of this type of linker-payload in plasma is improved.

[0016] To improve the hydrophilicity of ADCs, this invention introduces an ethylenediamine (DEA) structural fragment into the R-group side chain of Glu, and then modifies the DEA terminal amino group with a polyhydroxy alcohol group. Starting from the distance between the ADC and the payload, the highly hydrophilic polyhydroxy alcohol is used to fully mask the hydrophobicity of the payload, thereby improving the hydrophobicity and aggregation problems of ADCs coupled with hydrophobic payloads with a simple and easily prepared structure.

[0017] The advantages of the ADC based on the Linker-Payload of this invention include:

[0018] 1. The obtained ADC exhibits good in vitro and in vivo pharmacodynamic characteristics;

[0019] 2. The obtained ADC has excellent safety and a high maximum tolerated dose.

[0020] Therefore, in one aspect, the present invention provides a compound of formula (I), or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof:

[0021] The variables are as defined in this invention.

[0022] In another aspect, the present invention provides a compound of formula (II), or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof:

[0023] The variables are as defined in this invention.

[0024] In another aspect, the present invention provides a pharmaceutical composition comprising the compound described herein or its prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic or tautomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or adjuvant.

[0025] In another aspect, the present invention provides the use of the compound of the present invention or its prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic or tautomer, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of the present invention in the preparation of a medicament for treating a disease or condition and for reducing the severity of said disease or condition.

[0026] In another aspect, the present invention provides the compounds described herein or their prodrugs, hydrates, solvates, enantiomers, diastereomers, mesosomes, racemates, racemates or tautomers, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions described herein, for the treatment of diseases or conditions and for the reduction of the severity of said diseases or conditions.

[0027] In another aspect, the present invention provides a method for treating a disease or condition in a subject and for reducing the severity of said disease or condition, comprising administering to the subject a compound of the present invention or a prodrug thereof, a hydrate, a solvate, an enantiomer, a diastereomer, a meso compound, a racemic compound or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present invention.

[0028] On the other hand, this application provides a method for preparing an antibody-drug conjugate, which involves reducing the disulfide chain in the hinge region of the antibody or antibody fragment to generate a pair of cysteine ​​residues, and then subjecting the thiol group in the cysteine ​​residues to a substitution reaction with the linker of the compound of the present invention, thereby linking the compound of the present invention to the cysteine ​​thiol group of the antibody or antibody fragment to obtain an antibody-drug conjugate. The drug-antibody conjugation ratio (DAR) can be controlled according to the reaction conditions, for example, it is commonly between 2 and 8.

[0029] On the other hand, DAR (the average molar ratio of drug molecules to monoclonal antibody molecules in an antibody-drug conjugate obtained by conjugating a single monoclonal antibody molecule with a cytotoxic drug) can generally be determined by methods such as hydrophobic-interaction chromatography (HIC), reverse phase HPLC (RP-HPLC), polyacrylamide-SDS gel electrophoresis (SDS PAGE), liquid chromatography-mass spectrometry (LC-MS), and ultraviolet / visible spectroscopy (UV / Vis). Attached Figure Description

[0030] Figure 1: Comparative study of the hydrophilicity of the ADC of this invention.

[0031] Figure 2: Stability study of the ADC of the present invention in monkey plasma.

[0032] Figure 3: Stability study of the ADC of the present invention in mouse plasma.

[0033] Figure 4: The efficacy of the ADC of the present invention in a tumor model with high antigen expression.

[0034] Figure 5: Safety of the ADC of the present invention in a tumor model with high antigen expression.

[0035] Figure 6: The efficacy of the ADC of the present invention in a tumor model with low expression of antigen.

[0036] Figure 7: Safety of the ADC of the present invention in a tumor model with low expression of antigen.

[0037] Figure 8: Maximum tolerance study of the ADC of this invention in transgenic mice.

[0038] Invention Details

[0039] definition

[0040] Chemical definition

[0041] The definitions of specific functional groups and chemical terms are described in more detail below.

[0042] When listing a range of values, it is assumed that each value and the subranges within that range are included. For example, "C 1-6 Alkyl groups include C1, C2, C3, C4, C5, C6, and C6. 1-6 C 1-5 C 1-4 C 1-3 C 1-2 C 2-6 C 2-5 C 2- 4. C 2-3 C 3-6 C 3-5 C 3-4 C 4-6 C 4-5 and C 5-6 alkyl.

[0043] “C 1-6 "Alkyl" refers to a straight-chain or branched saturated hydrocarbon group having 1 to 6 carbon atoms. In some embodiments, C 1-4 Alkyl groups are preferred. In some embodiments, C 1-2 Alkyl groups are preferred. C 1-6 Examples of alkyl groups include: methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tert-pentyl (C5), and n-hexyl (C6). The term "C" is used in conjunction with the preceding text. 1-6 "Alkyl" also includes heteroalkyl, wherein one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen (O), sulfur (S), nitrogen (N), boron (B), silicon (Si), phosphorus (P)). The alkyl group may be optionally substituted by one or more substituents, for example, by 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. Common alkyl abbreviations include: Me (-CH3), Et (-CH2CH3), iPr (-CH(CH3)2), nPr (-CH2CH2CH3), n-Bu (-CH2CH2CH2CH3), or i-Bu (-CH2CH(CH3)2).

[0044] "Halogen" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).

[0045] Therefore, "C" 1-6 "Halogenated alkyl" refers to the above "C 1-6"alkyl" is substituted with one or more halogen groups. In some embodiments, C 1-3 Haloalkyl groups are particularly preferred, and C4 groups are more preferred. 1-2 Halogenated alkyl groups. Exemplary alkyl halogenated groups include, but are not limited to: -CF3, -CH2F, -CHF2, -CHFCH2F, -CH2CHF2, -CF2CF3, -CCl3, -CH2Cl, -CHCl2, 2,2,2-trifluoro-1,1-dimethyl-ethyl, etc. The alkyl halide group can be substituted at any available junction, for example, by 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0046] “C 2-6 "Alkenyl" refers to a straight-chain or branched hydrocarbon group having 2 to 6 carbon atoms and one or more carbon-carbon double bonds (e.g., 1, 2, or 3 carbon-carbon double bonds). The one or more carbon-carbon double bonds can be internal (e.g., in a 2-butenyl group) or terminal (e.g., in a 1-butenyl group). In some embodiments, C 2-4 Alkenyl groups are particularly preferred. Examples of such alkenyl groups include, but are not limited to: vinyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), hexenyl (C6), and so on. Regardless of whether the alkenyl group is preceded by "substituted," each alkenyl group is optionally substituted independently, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent, with suitable substituents defined below.

[0047] “C 2-6 "Alkyne" refers to a straight-chain or branched hydrocarbon group having 2 to 6 carbon atoms, one or more carbon-carbon triple bonds (e.g., 1, 2, or 3 carbon-carbon triple bonds), and optionally one or more carbon-carbon double bonds (e.g., 1, 2, or 3 carbon-carbon double bonds). In some embodiments, C 2-4 The alkynyl group is particularly preferred. In some embodiments, the alkynyl group does not contain any double bonds. One or more carbon triple bonds may be internal (e.g., in 2-butynyl) or terminal (e.g., in 1-butynyl). Examples of the alkynyl group include, but are not limited to: ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentyynyl (C5), hexynyl (C6), and so on. Regardless of whether the alkynyl group is preceded by the word "substituted," each alkynyl group is optionally substituted independently, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent, with suitable substituents defined below.

[0048] “C 3-10"Cycloalkyl" refers to a non-aromatic cyclic hydrocarbon group having 3 to 10 ring carbon atoms and zero heteroatoms. In some embodiments, C 3-8 cycloalkyl, C 4-6 Cycloalkyl groups are preferred, C 3-6 Cycloalkyl groups are particularly preferred, and C10 is more preferred. 5-6 Cycloalkyl groups. Cycloalkyl groups also include ring systems in which the aforementioned cycloalkyl ring is fused with one or more aryl or heteroaryl groups, wherein the bonding point is on the cycloalkyl ring, and in such cases, the number of carbons continues to represent the number of carbons in the cycloalkyl system. Exemplary cycloalkyl groups include, but are not limited to: cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptanetrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptyl (C7), bicyclo[2.2.2]octyl (C8), cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C9), etc. 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C9), decahydronaphthyl (C9) 10 ), spiro[4.5]decyl(C 10 ), borneol, adamantyl, etc. Regardless of whether the cycloalkyl group is modified with "substituted", each cycloalkyl group is independently and optionally substituted, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent, with suitable substituents defined as follows.

[0049] “C 3-8 "Cycloalkylene" refers to the alkylene oxide with the "C" removed. 3-8 A divalent group formed by another hydrogen atom of a cycloalkyl group.

[0050] "3-10 membered heterocyclic groups" refer to groups with a 3- to 10-membered non-aromatic ring system having a ring carbon atom and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon. In heterocyclic groups containing one or more nitrogen atoms, the linkage can be a carbon or nitrogen atom, provided that the valence allows. In some embodiments, 4-10 membered heterocyclic groups are preferred, which are 4-10 membered non-aromatic ring systems having a cyclic carbon atom and 1 to 4 cyclic heteroatoms; in some embodiments, 5-10 membered heterocyclic groups are preferred, which are 5-10 membered non-aromatic ring systems having a cyclic carbon atom and 1 to 4 cyclic heteroatoms; in some embodiments, 3-8 membered heterocyclic groups are preferred, which are 3-8 membered non-aromatic ring systems having a cyclic carbon atom and 1 to 3 cyclic heteroatoms; in some embodiments, 3-6 membered heterocyclic groups are particularly preferred, which are 3-6 membered non-aromatic ring systems having a cyclic carbon atom and 1 to 3 cyclic heteroatoms; more preferably, 5-6 membered heterocyclic groups are 5-6 membered non-aromatic ring systems having a cyclic carbon atom and 1 to 3 cyclic heteroatoms. Heterocyclic groups also include cyclic systems in which the aforementioned heterocyclic ring is fused with one or more cycloalkyl, aryl, or heteroaryl groups, wherein the connection point is on the heterocyclic ring; and in such cases, the number of ring members continues to indicate the number of ring members in the heterocyclic ring system. Regardless of whether the heterocyclic group is preceded by the word "substituted," each of the heterocyclic groups may be optionally substituted independently, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent, with suitable substituents defined below.

[0051] "3-8 membered heterocyclic group" refers to a divalent group formed by removing the other hydrogen atom of the "3-8 membered heterocyclic group".

[0052] Exemplary 3-membered heterocyclic groups containing one heteroatom include, but are not limited to: azircyclopropane, oxacyclopropane, and thiorenyl. Exemplary 4-membered heterocyclic groups containing one heteroatom include, but are not limited to: azircyclobutane, oxacyclobutane, and thiorenyl. Exemplary 5-membered heterocyclic groups containing one heteroatom include, but are not limited to: tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolidinyl, and pyrrolidin-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to: dioxasulfuranyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to: triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to: piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to: piperazinyl, morpholinyl, dithianyl, and dioxane. Exemplary 6-membered heterocyclic groups containing three heteroatoms include, but are not limited to: triazinanyl. Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to: azirheptanyl, oxeheptanyl, and thionylheptanyl. Exemplary 8-membered heterocyclic groups containing one heteroatom include, but are not limited to: azirheptanyl, oxeheptanyl, and thionylheptanyl. Exemplary 5-membered heterocyclic groups fused with a C6 aryl ring (also referred to herein as 5,6-bicyclic heterocyclic groups) include, but are not limited to: dihydroindolyl, isodihydroindolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, benzoxazolinoneyl, etc. Exemplary 6-membered heterocyclic groups fused with a C6 aryl ring (also referred to herein as 6,6-bicyclic heterocyclic groups) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, etc.

[0053] “C 6-10 "Aryl" refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6 or 10 shared π electrons arranged in a ring) having 6-10 ring carbon atoms and zero heteroatoms. In some embodiments, the aryl group has six ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, the aryl group has ten ring carbon atoms ("C... 10 "Aryl"; for example, naphthyl, such as 1-naphthyl and 2-naphthyl). In some embodiments, C 6-10Aryl groups are particularly preferred, and more preferably C6 aryl groups. Aryl groups also include ring systems in which the aforementioned aryl ring is fused with one or more cycloalkyl or heterocyclic groups, and the connection point is on the aryl ring, in which case the number of carbon atoms continues to represent the number of carbon atoms in the aryl ring system. Regardless of whether the aryl group is preceded by the word "substituted," each aryl group may be optionally substituted independently, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent, with suitable substituents defined below.

[0054] “C 6-10 "Aspartic" refers to the product with the "C" removed. 6-10 The other hydrogen atom of the aryl group forms a divalent group.

[0055] "5-10-membered heteroaryl" refers to a group comprising a 4n+2 aromatic ring system of a 5-10-membered monocyclic or bicyclic ring having a ring carbon atom and 1-4 ring heteroatoms (e.g., having 6 or 10 shared π electrons arranged in a ring), wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In heteroaryl containing one or more nitrogen atoms, the bonding point can be a carbon or nitrogen atom, provided the valence allows. A heteroaryl bicyclic system may include one or more heteroatoms in one or both rings. Heteroaryl also includes ring systems in which the aforementioned heteroaryl ring is fused with one or more cycloalkyl or heterocyclic groups, and the bonding point is on the heteroaryl ring, in which case the number of carbon atoms continues to represent the number of carbon atoms in the heteroaryl ring system. In some embodiments, 5-6-membered heteroaryl is particularly preferred, which is a 4n+2 aromatic ring system of a 5-6-membered monocyclic or bicyclic ring having a ring carbon atom and 1-4 ring heteroatoms. In some embodiments, a 5-membered heteroaryl group is particularly preferred, which is a 4n+2 aromatic ring system of a 5-membered monocyclic or bicyclic ring having a cyclic carbon atom and 1-4 cyclic heteroatoms. Regardless of whether the heteroaryl group is preceded by "substituted", each of the heteroaryl groups is optionally substituted independently, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent, with suitable substituents defined as follows.

[0056] "5-10 heteroaryl" refers to a divalent group formed by removing the other hydrogen atom of the "5-10 heteroaryl".

[0057] Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to: pyrrole, furanyl, and thiophene. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to: imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to: triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to: tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to: pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to: pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to: triazinyl and tetraazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to: azirheptatrienyl, oxaheptatrienyl, and thioheptatrienyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to: indolyl, isoindolyl, indazole, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzoimidazolyl, benzoxazolyl, benzoisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzoisothiazolyl, benzothiadiazolyl, indazinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to: naphridinyl, pteridinyl, quinolinyl, isoquinolinyl, zolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

[0058] In this application, the terms “optional” or “optionally” generally refer to an event or environment described subsequently that may but does not have to occur, and the description includes situations in which the event or environment occurs or does not occur. For example, “optionally alkyl-substituted heterocyclic group” means that an alkyl group may but does not have to be present, and the description can include cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.

[0059] Exemplary substituents on carbon atoms include, but are not limited to: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa -ON(R) bb )2、-N(R bb )2、-N(R bb )3 + X - -N(OR) cc )R bb -SH, -SR aa -SSR cc -C(=O)R aa -CO2H, -CHO, -C(OR) cc )2、-CO2R aa -OC(=O)R aa -OCO2R aa、-C(=O)N(R bb )2、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3、-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)2R aa 、-OP(=O)2R aa 、-P(=O)(R aa )2、-OP(=O)(R aa )2、-OP(=O)(OR cc )2、-P(=O)2N(Rbb )2、-OP(=O)2N(R bb )2、-P(=O)(NR bb )2、-OP(=O)(NR bb )2、-NR bb P(=O)(OR cc )2、-NR bb P(=O)(NR bb )2、-P(R cc )2、-P(R cc )3、-OP(R cc )2、-OP(R cc )3、-B(R aa 2. -B(OR) cc )2、-BR aa (OR cc ), alkyl, haloalkyl, alkenyl, ynyl, carbocyclic, heterocyclic, aryl, and heteroaryl, wherein each alkyl, alkenyl, ynyl, carbocyclic, heterocyclic, aryl, and heteroaryl is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution;

[0060] Or the two hydrogen-bearing groups on the carbon atom: =O, =S, =NN(R) bb )2、=NNR bb C(=O)R aa =NNR bb C(=O)OR aa =NNR bb S(=O)2R aa =NR bb or = NOR cc replace;

[0061] R aa Each of them is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl, or two R aa Groups are combined to form heterocyclic or heteroaryl rings, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution;

[0062] R bb Each is independently selected from: hydrogen, -OH, -OR aa -N(R) cc )2、-CN、-C(=O)R aa -C(=O)N(R) cc )2、-CO2R aa -SO2R aa -C(=NR)cc OR aa -C(=NR) cc )N(R cc )2、-SO2N(R cc )2、-SO2R cc -SO2OR cc -SOR aa -C(=S)N(R) cc )2、-C(=O)SR cc -C(=S)SR cc -P(=O)2R aa -P(=O)(R aa )2、-P(=O)2N(R cc )2、-P(=O)(NR cc 2. Alkyl, haloalkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl, or two R bb Groups are combined to form heterocyclic or heteroaryl rings, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution;

[0063] R cc Each is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, ynyl, carbocyclic, heterocyclic, aryl, and heteroaryl, or two R groups. cc Groups are combined to form heterocyclic or heteroaryl rings, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution;

[0064] R dd Each is independently selected from: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee -ON(R) ff )2、-N(R ff )2,、-N(R ff )3 + X - -N(OR) ee )R ff -SH, -SR ee -SSR ee -C(=O)R ee -CO2H, -CO2R ee -OC(=O)R ee -OCO2R ee -C(=O)N(R) ff )2、-OC(=O)N(Rff )2、-NR ff C(=O)R ee -NR ff CO2R ee -NR ff C(=O)N(R ff )2、-C(=NR ff OR ee -OC(=NR) ff )R ee -OC(=NR) ff OR ee -C(=NR) ff )N(R ff )2、-OC(=NR ff )N(R ff )2、-NR ff C(=NR ff )N(R ff )2、-NR ff SO2R ee -SO2N(R) ff )2、-SO2R ee -SO2OR ee -OSO2R ee -S(=O)R ee 、-Si(R ee )3、-OSi(R ee 3. -C(=S)N(R) ff )2、-C(=O)SR ee -C(=S)SR ee -SC(=S)SR ee -P(=O)2R ee -P(=O)(R ee )2、-OP(=O)(R ee )2、-OP(=O)(OR ee 2. Alkyl, haloalkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. gg Group substitution, or two geminal radicals dd Substituents can combine to form =O or =S;

[0065] R ee Each is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, carbocyclic, aryl, heterocyclic, and heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl is independently surrounded by 0, 1, 2, 3, 4, or 5 R groups. gg Group substitution;

[0066] R ff Each is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, ynyl, carbocyclic, heterocyclic, aryl, and heteroaryl, or two R groups. ff The groups combine to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. gg Group substitution;

[0067] R gg Each of these is independently: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1- 6-alkyl, -ON(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + X - -NH(C 1-6 Alkyl)2 + X - -NH2(C 1-6 alkyl) + X - -NH3 + X - -N(OC) 1-6 Alkyl)(C 1-6 Alkyl), -N(OH)(C 1-6 Alkyl groups, -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl group, -CO2H, -CO2(C 1- 6-alkyl), -OC (=O)(C 1-6 Alkyl), -OCO2(C 1-6 Alkyl groups, -C(=O)NH2, -C(=O)N(C 1-6 Alkyl)2、-OC(=O)NH(C 1-6 Alkyl), -NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 alkyl), -NHCO2(C 1-6 Alkyl), -NHC(=O)N(C 1-6 Alkyl)2、-NHC(=O)NH(C 1-6 Alkyl groups, -NHC(=O)NH2, -C(=NH)O(C 1-6 Alkyl), -OC (=NH)(C 1-6Alkyl group), -OC (=NH)OC 1-6 Alkyl group, -C(=NH)N(C 1-6 Alkyl)2、-C(=NH)NH(C 1-6 Alkyl groups, -C(=NH)NH2, -OC(=NH)N(C 1- 6-alkyl)2、-OC(NH)NH(C 1-6 Alkyl groups, -OC(NH)NH2, -NHC(NH)N(C 1-6 Alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 alkyl), -SO2N(C 1-6 alkyl)2、-SO2NH(C 1-6 Alkyl groups, -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C) 1- 6-alkyl)3、-OSi(C 1-6 Alkyl)3, -C(=S)N(C 1-6 Alkyl)2、C(=S)NH(C 1-6 Alkyl), C(=S)NH2, -C(=O)S(C 1-6 Alkyl), -C(=S)SC 1-6 Alkyl, -SC (=S)SC 1-6 Alkyl group, -P(=O)2(C 1-6 Alkyl), -P(=O)(C 1-6 Alkyl)2、-OP(=O)(C 1-6 Alkyl)2、-OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Haloalkyl, C2-C6 alkenyl, C2-C6 ynyl, C3-C7 carbocyclic, C6-C 10 Aryl, C3-C7 heterocyclic, C5-C 10 heteroaryl; or two ethryl groups gg Substituents can combine to form =O or =S; where X - It is a counterion.

[0068] Exemplary substituents on the nitrogen atom include, but are not limited to: hydrogen, -OH, -OR aa -N(R) cc )2、-CN、-C(=O)R aa -C(=O)N(R) cc )2、-CO2R aa -SO2Raa -C(=NR) bb )R aa -C(=NR) cc OR aa -C(=NR) cc )N(R cc )2、-SO2N(R cc )2、-SO2R cc -SO2OR cc -SOR aa -C(=S)N(R) cc )2、-C(=O)SR cc -C(=S)SR cc -P(=O)2R aa -P(=O)(R aa )2、-P(=O)2N(R cc )2、-P(=O)(NR cc 2. Alkyl, haloalkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl, or two R atoms attached to a nitrogen atom. cc The groups combine to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, and heteroaryl group is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution, wherein R aa R bb R cc and R dd As stated above.

[0069] "Deuterated" or "deuterium" refers to the substitution of one or more hydrogen atoms in a compound or group by deuterium; deuteration can be monosubstituted, disubstituted, polysubstituted, or fully substituted. The terms "one or more deuterated" and "one or more deuterated" are used interchangeably. The deuterium isotope content at the deuterated position is at least 0.015% greater than the natural deuterium isotope content, preferably greater than 30%, more preferably greater than 50%, more preferably greater than 75%, more preferably greater than 95%, and more preferably greater than 99%.

[0070] In this application, the term "compound" generally refers to a substance having two or more different elements. For example, the compound in this application can be an organic compound, a compound with a molecular weight of less than 500, less than 1000, more than 1000, or more than 10,000 or 100,000. In this application, a compound can also refer to a compound linked by chemical bonds. For example, it can be a compound in which one or more molecules with a molecular weight of less than 1000 are linked by chemical bonds to a biological macromolecule, such as a polysaccharide, protein, nucleic acid, polypeptide, etc. For example, the compound in this application can include a compound in which a protein is linked to one or more molecules with a molecular weight of less than 1000, a compound in which a protein is linked to one or more molecules with a molecular weight of less than 10,000, or a compound in which a protein is linked to one or more molecules with a molecular weight of less than 100,000.

[0071] As used herein, the term "compound of this application" refers to the compound of this application. The term also includes various pharmaceutically acceptable salts, prodrugs, hydrates, solvates, enantiomers, diastereomers, mesosomes, racemates, racemates, or tautomers of the compounds of this application.

[0072] biological definition

[0073] In this application, the term "ligand" generally refers to a macromolecular compound that recognizes and binds to cell-associated antigens or receptors. The role of a ligand can be to present a drug to a population of cells bound to it. These ligands include, but are not limited to, protein hormones, lectins, growth factors, antibodies, or other molecules that can bind to cells, receptors, and / or antigens. In this application, a ligand can be represented as Ab, and the ligand antigen forms a linker bond with a linker unit via a heteroatom on the ligand. It can be an antibody or its antigen-binding fragment, and the antibody can be selected from chimeric antibodies, humanized antibodies, fully human antibodies, or murine antibodies; the antibody can be a monoclonal antibody. For example, the antibody can be an antibody or its antigen-binding fragment targeting a target selected from the group consisting of:

[0074] HER2, Trop-2, Claudin-6, Claudin-9, Claudin-18.2, EGFR, c-Met, CD19, PSMA, Muc1, BCMA, PD-L1, CD33, CD30, CD22, CD79b, Nectin-4, CD19, Tissue Factor, FRα, B7-H3, B7-H4, CDH3, CDH6, CDH17, ALPP, CD56, CD37, HER3, ROR1, MSLN, TNF-α, CD25, ENPP 3. Muc1, Axl, CD20, ROR2, GPNMB, CEACAM5, CEACAM6, CD138, GC-C, LIV-1, CA6, FUT3, IGF-1R, CTLA4, RNF43, DPEP3, 5T4, I TGB6, EFNA4, CD228, Notch3, CD46, CAIX, SLAMF6, ADAM9, GD3, TDGF1, SLAMF2, CLL-1, CD123, FCRL5, TIM1, sTn, ETB, Globo H, CD38, Ly6E, SLITRK6, GPR20, FGFR2, Muc16, CD5 1. SLAMF7, LAMP-1, CD74, CCR7, PTK7, SEZ6, LYFD3, TAA, PRL receptor, FGFR3, KAAG1, STEAP1, Flt3, Muc1, LRRC15, CD44, CD70, EphA2, CXCR4, DDR1, DKL1, FOLR, CD45, DSG2, ALK, TRAIL, EpCAM, VEGFR2, CD47, CD49, SSEA-4, DCLK1, OacGD2, CD73, ENO1, BSG, CD24, GLUT1 and GPRC5D, preferably HER2, HER3, EGFR, Trop-2, Claudin-6, Claudin-18.2, B7-H3, B7-H4, CDH3, CDH6, CDH17, FRα, ROR1, ALPP, CEACAM5, CEACAM6 or FOLR.

[0075] In this application, the term "coupler" generally refers to a compound prepared by one or more chemical reactions, or a compound connected to each other by one or more connecting structures such as a bridge, spacer, or connecting portion.

[0076] In this application, the term "HER2" generally refers to human epidermal growth factor receptor 2 (HER2), for example, the term "HER2" refers to any natural HER2 from any human source. The term also covers "full-length" and unprocessed HER2, as well as any form of HER2 derived from cells and processed (e.g., mature protein). The term also covers naturally occurring variants and isotypes of HER2, such as splice variants or allelic variants. For example, Uniprot accession number P04626 provides a description of HER2 and its sequence.

[0077] In this application, the terms "B7-H3" and "CD276" generally refer to a type I transmembrane protein belonging to the B7 immune co-stimulatory and co-inhibitory family. The B7-H3 protein is encoded by the chromosome 15q24 gene and structurally comprises 316 amino acids, including an extracellular domain, a transmembrane domain, and a short intracellular domain. The intracellular domain of the B7-H3 protein is very short, and no known signaling motif exists.

[0078] In this application, the term "chimeric antibody" generally refers to an antibody formed by fusing the variable region of a murine antibody with the constant region of a human antibody, which can alleviate the immune response induced by murine antibodies. To establish a chimeric antibody, a hybridoma that secretes murine-specific monoclonal antibodies can be created. The variable region gene can then be cloned from the murine hybridoma cells, and the constant region gene of a human antibody can be cloned as needed. The murine variable region gene and the human constant region gene can be linked to form a chimeric gene, which is then inserted into an expression vector. The chimeric antibody molecule can then be expressed in eukaryotic or prokaryotic systems.

[0079] In this application, the term "humanized antibody," also known as a CDR-grafted antibody, generally refers to an antibody generated by grafting a mouse CDR sequence into a human antibody variable region framework, i.e., an antibody generated within a different type of human germline antibody framework sequence. This can overcome the heterologous response induced by chimeric antibodies carrying a large amount of mouse protein components. Such framework sequences can be obtained from public DNA databases containing germline antibody gene sequences or from publicly available references. For example, germline DNA sequences of human heavy chain and light chain variable region genes can be found in the "VBase" human germline sequence database.

[0080] In this application, the terms "fully human antibody," "fully human antibody," or "completely human antibody," also known as "fully human monoclonal antibody," refer to antibodies whose variable and constant regions can both be human-derived, thus eliminating immunogenicity and toxic side effects. The development of monoclonal antibodies has gone through four stages: murine monoclonal antibodies, chimeric monoclonal antibodies, humanized monoclonal antibodies, and fully human monoclonal antibodies. The antibody or ligand described in this application can be a fully human monoclonal antibody. Related technologies for the preparation of fully human antibodies include: human hybridoma technology, EBV-transformed B lymphocyte technology, phage display technology, transgenic mouse antibody preparation technology, and single B cell antibody preparation technology, etc.

[0081] In this application, the term "CDR" generally refers to one of the six hypervariable regions within the variable domain of an antibody that primarily facilitate antigen binding. One of the most commonly used definitions of the six CDRs is provided by Kabat EA et al., Chothia et al., and MacCallum et al. As used in this application, the Kabat definition of CDR can be applied to CDR1, CDR2, and CDR3 (CDRL1, CDRL2, CDRL3 or LK, L2, L3) of the light chain variable domain, and CDRK, CDR2, and CDR3 (CDRH1, CDRH2, CDRH3 or HI, H2, H3) of the heavy chain variable domain.

[0082] In this application, the term "linker" generally refers to a chemical structural fragment or bond that is connected at one end to a group and at the other end to another group. It may also refer to a linker that is connected to other linkers before being linked to a drug and / or ligand. The direct or indirect linker can refer to the group directly connecting to the ligand via a covalent bond, or it can refer to the ligand being connected via a linker. For example, chemical structural fragments or bonds containing acid-labile linker structures (e.g., hydrazones), protease-sensitive (e.g., peptidase-sensitive) linker structures, light-labile linker structures, dimethyl linker structures, or disulfide-containing linker structures can be used as linkers.

[0083] In this application, the term "linking group" generally refers to a group that has the ability to be linked to another group. For example, a compound having a linking group can achieve the linkage of the compound to another group through a coupling reaction between the linking group and another group. For example, a maleimide group can serve as a linking group.

[0084] In this application, the term "pharmaceutical unit" generally refers to a chemical moiety that directly or indirectly conjugates an antibody or antigen-binding fragment to form an immunoconjugate. For example, a "pharmaceutical unit" includes, but is not limited to, compounds with antitumor activity described herein. For example, pharmaceutical units include topoisomerase inhibitors.

[0085] In this application, the term "disease associated with the expression of a target" generally refers to a disease in which the occurrence and / or progression of the disease is associated with the expression level of the target. For example, high expression means that the expression level of a target is increased in cells from a disease region, such as a specific tissue or organ of a patient, relative to the expression level in normal cells from the tissue or organ. Or, for example, low expression means that the expression level of a target is decreased in cells from a disease region, such as a specific tissue or organ of a patient, relative to the expression level in normal cells from the tissue or organ. Or, for example, positive expression means that cells from a disease region, such as a specific tissue or organ of a patient, express a target. Or, negative expression means that cells from a disease region, such as a specific tissue or organ of a patient, do not express a target. For example, the characteristics of target expression can be determined by standard assays known in the art.

[0086] As used herein, “antibody” is used in its broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, provided they exhibit the desired biological activity. Antibodies can be mouse, human, humanized, chimeric, or derived from other species. Antibodies are proteins produced by the immune system capable of recognizing and binding to specific antigens. Target antigens generally have numerous binding sites, also called epitopes, recognized by the CDRs of various antibodies. Antibodies that specifically bind to different epitopes have different structures. Therefore, an antigen can have more than one corresponding antibody. Antibodies include full-length immunoglobulin molecules or the immunoactive portion of full-length immunoglobulin molecules, i.e., molecules containing antigens or portions thereof that specifically bind to the target of interest, including, but not limited to, cancer cells or cells that produce autoantibodies associated with autoimmune diseases. The immunoglobulins described in this application can have any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecules. Immunoglobulins can be derived from any species. However, in one aspect, immunoglobulins are derived from humans, mice, or rabbits. An "antibody fragment" can comprise a portion of a full-length antibody, generally its antigen-binding region or variable region. Examples of antibody fragments include: Fab, Fab\F(ab')2, and Fv fragments; biantibodies; linear antibodies; minibody; fragments prepared from Fab expression libraries; anti-idiotypic (anti-Id) antibodies; CDR (complementarity-determining region); and any of the above epitope-binding fragments that bind to cancer cell antigens, viral antigens, or microbial antigens in an immune-specific manner; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. The antibodies constituting the antibody-drug conjugates in this application can retain their original wild-state antigen-binding capacity. Therefore, the antibodies in this application can, for example, specifically bind to antigens. The antigens involved include, for example, tumor-associated antigens (TAAs), cell surface receptor proteins and other cell surface molecules, cell survival regulators, cell proliferation regulators, molecules associated with tissue growth and differentiation (such as those known or anticipated to be functional), lymphokines, cytokines, molecules involved in cell circulation regulation, molecules involved in angiogenesis, and molecules associated with angiogenesis (such as those known to be functional). The antigens bound by the antibodies can be one or a subset of the above categories, while other subsets include other molecules / antigens with specific properties (compared to the target antigen). Antibodies used in antibody-drug conjugates include, but are not limited to, antibodies against cell surface receptors and tumor-associated antigens. Such tumor-associated antigens are well known in the art and can be prepared using antibody preparation methods and information well known in the art.These targets can be specifically expressed on the surface of one or more cancer cells, while being expressed sparingly or not at all on the surface of one or more non-cancer cells. Typically, such tumor-associated peptides can be overexpressed on the surface of cancer cells compared to non-cancer cells.

[0087] In this application, the term "amino acid" refers to the basic structural unit that makes up proteins and is the basis for later protein modifications in organisms. There are a total of 20 naturally occurring amino acids. In addition to these basic amino acids, organisms can synthesize derived amino acid types such as hydroxyproline and hydroxylysine. In fireflies, even D-type amino acids are synthesized. Naturally occurring amino acids are generally L-type, but this invention also includes D-type amino acids. The amino acids used in this invention are shown in the table below:

[0088] In this application, the term "peptide residue / oligopeptide residue" generally refers to a residue comprising two or more amino acid residues linked by peptide bonds. For example, the two or more amino acids in a peptide residue may be optionally substituted. For example, the peptide residues in this application may be selected from the group consisting of: valine-citrulline (Val-Cit), valine-alanine (Val-Ala), valine-lysine (Val-Lys), phenylalanine-lysine (Phe-Lys), lysine-lysine (Lys-Lys), alanine-lysine (Ala-Lys), phenylalanine-citrulline (Phe-Cit), leucine-citrulline (Leu-Cit), isoleucine-citrulline (I... Lysine-Val-Cit), Phenylalanine-Alanine (Phe-Ala), Lysine-Val-Cit), Lysine-Val-Alanine (Lys-Val-Ala), Valine-Lys-Glycine (Val-Lys-Gly), Glycine-Val-Lys, Glycine-Val-Alanine (Gly-Val-Ala), Glutamic Acid-Val-Alanine (Glu-V) al-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), glutamine-valine-alanine (Gln-Val-Ala), glutamine-valine-citrulline (Gln-Val-Cit), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-asparagine (Ala-Ala-Asn), phenylalanine-phenylalanine-lysine (Phe-Phe-Lys), glycine- Phenylalanine-lysine (Gly-Phe-Lys), leucine-alanine-leucine (Leu-Ala-Leu), isoleucine-alanine-leucine (Ile-Ala-Leu), valine-alanine-valine (Val-Ala-Val), glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), (Ala-Leu-Ala-Leu), and (Gly-Phe-Leu-Gly).Preferably selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), glutamine-valine-alanine (Gln-Val-Ala), glutamine-valine-citrulline (Gln-Val-Cit), valine-lysine (Val-Lys), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-asparagine (Ala-Ala-Asn), and glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), and preferably selected from the group consisting of: valine-citrulline (Val-Cit), valine-alanine (Val-Ala), valine- Lysine (Val-Lys), phenylalanine-lysine (Phe-Lys), lysine-valine-citrulline (Lys-Val-Cit), lysine-valine-alanine (Lys-Val-Ala), glutamine-valine-alanine (Gln-Val-Ala), glutamine-valine-citrulline (Gln-Val-Cit), and glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), preferably selected from the group consisting of: valine-citrulline (Val-Cit), valine-alanine (Val-Ala), valine-lysine (Val-Lys), lysine-valine-citrulline (Lys-Val-Cit), lysine-valine-alanine (Lys-Val-Ala), and glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly).

[0089] In this application, the term "polyethylene glycol group / polyethylene glycol group" generally refers to a group of residues consisting of one or more ethylene glycol residues linked together. For example, a polyethylene glycol group may contain -(CH2CH2O). p - where p is a number that is at least 1. For example, the polyethylene glycol group in this application may be optionally substituted.

[0090] In this application, the term "polysarcosine residue / polysarcosine residue" generally refers to a residue consisting of one or more sarcosine residues linked together. For example, a polysarcosine residue may contain -(COCH2N(CH3)). q - where q is a number that is at least 1.

[0091] In this application, the term "pentose sugar" refers to a monosaccharide containing five carbon atoms in its molecule, also known as a pentose. Pentoses are widely distributed in the biological world and play an important role in life activities. The main types are D-xylose, L-arabinose, D-ribose, and its derivative D-2-deoxyribose. Pentoketoses that are intermediate products of sugar metabolism include D-ribulose and D-xylulose.

[0092] In this application, the term "hexose" refers to a monosaccharide containing six carbon atoms, also known as a hexose. Hexoses are the most widely distributed and abundant in nature, and are most closely related to the body's nutritional metabolism. Hexoses containing an aldehyde group at position 1 are called aldoses, and hexoses containing a ketone group at position 2 are called ketoses. Five of the six carbon atoms in a hexose are attached to hydroxyl groups (-OH), and the remaining carbon atom belongs to an aldehyde group (-COH) or a ketone group (-CO-). Important aldoses include D-glucose, D-galactose, and D-mannose; ketoses include D-fructose.

[0093] In this application, the term "tumor" generally refers to any new pathological tissue proliferation. For the purposes of this application, angiogenesis is part of the characteristics of a tumor. A tumor may be benign or malignant. The term "tumor" is generally used to refer to a benign or malignant tumor, while the term "cancer" is generally used to refer to a malignant tumor, which may be metastatic or non-metastatic. Tumors that can be treated with the methods of this application are selected from the following group: breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, rectal cancer, gastric cancer, glioma, and mesothelioma. When used for research purposes, these tissues can be isolated from readily available resources using methods well known to those skilled in the art.

[0094] Other definitions

[0095] In this application, the term "comprising" generally means including the explicitly specified features, but does not exclude other elements. The terms "above" and "below" generally refer to situations that include the stated number.

[0096] In this application, the term "about" generally refers to a variation within a range of 0.5% to 10% above or below a specified value, such as a variation within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.

[0097] As used herein, the term "pharmaceutically acceptable salt" refers to acid or base addition salts of the compounds of the present invention that are suitable for contact with patient tissues within the limits of reliable medical judgment, without producing undue toxicity, irritation, allergic reactions, etc., and are effective for their intended use, including (where possible) zwitterionic forms of the compounds of the present invention.

[0098] Pharmaceutically acceptable salts can be sulfates, pyrosulfates, bisulfates, sulfites, nitrates, borates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, etc., prepared from inorganic acids. Representative salts include hydrobromide, hydrochloride, sulfates, bisulfates, nitrates, borates, and phosphates. Salts can also be prepared from organic acids, such as aliphatic monocarboxylic and dicarboxylic acids, phenyl-substituted alkyl acids, hydroxyalkyl acids, alkyl diacids, aromatic acids, and aliphatic and aromatic sulfonic acids. Representative salts include acetates, propionates, valerates, oleates, palmitates, stearates, laurates, caprylates, isobutyrates, oxalates, malonates, succinates, caprylates, sebacic acid salts, fumarates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, naphthates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, maleates, tartrates, methanesulfonates, glucono-p-ethyl, lactobionates, laurylsulfonates, and hydroxyethanesulfonates. Pharmaceutically acceptable salts may include alkali metal and alkaline earth metal-based cations, such as sodium, lithium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine. It also covers salts of amino acids, such as arginine salts, gluconates, galacturons, etc. (see, for example, Berge S. et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977; 66: 1-19, incorporated herein by reference).

[0099] This invention also includes isotopically labeled compounds (isotope variants) that are equivalent to the general formulas or specific compounds described in this application, but in which one or more atoms are replaced by atoms with atomic masses or mass numbers different from those commonly found in nature. Examples of isotopes that can be introduced into the compounds of this invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, respectively, for example... 2 H, 3 H, 13 C 11 C 14 C 15 N、 18 O、 17 O、31 P, 32 P, 35 S, 18 F and 36 Cl. Other isotopes of the present invention containing the aforementioned isotopes and / or other atoms, their prodrugs, and pharmaceutically acceptable salts of said compounds or said prodrugs are all within the scope of this invention. Certain isotope-labeled compounds of the present invention, for example, those incorporating radioactive isotopes (e.g.,...) 3 H and 14 Those in category C) can be used for drug and / or substrate tissue distribution determination. Tritium, i.e. 3 H and carbon-14, i.e. 14 Carbon isotopes are particularly preferred because they are easy to prepare and detect. Additionally, heavier isotopes such as deuterium (i.e.,...) are preferred. 2 H) substitution is preferred in some cases because its higher metabolic stability can provide therapeutic benefits, such as prolonged in vivo half-life or reduced dosage requirements. Isotope-labeled compounds of the present invention and their prodrugs can generally be prepared by replacing non-isotope-labeled reagents with readily available isotope-labeled reagents when performing the processes described below and / or the techniques disclosed in the examples and preparation examples.

[0100] The compounds of this invention comprise one or more asymmetric centers and therefore can exist in a variety of stereoisomeric forms, such as enantiomers and / or diastereomers. For example, the compounds of this invention may be individual enantiomers, diastereomers, or geometric isomers (e.g., cis and trans isomers), or may be in the form of mixtures of stereoisomers, including racemic mixtures and mixtures rich in one or more stereoisomers. The isomers can be separated from the mixture by methods known to those skilled in the art, including chiral high-performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis.

[0101] The compounds of this invention can exist as tautomers. Tautomers are functional group isomers that arise from the rapid movement of an atom between two positions in a molecule. A tautomer is a special type of functional group isomer; a pair of tautomers can interconvert, but usually the more stable isomer is the dominant form. The most prominent examples are enol and keto tautomers.

[0102] In this application, the term "pharmaceutical composition" generally refers to a mixture containing one or more of the compounds described in this application or their physiologically / pharmaceutical-grade salts or prodrugs, along with other chemical components, such as physiologically / pharmaceutical-grade carriers and excipients. Pharmaceutical compositions can facilitate administration to an organism, promote the absorption of the active ingredient, and thereby exert its biological activity. Conventional methods for preparing pharmaceutical compositions are described in the art.

[0103] In this application, the term "pharmaceutically acceptable carrier" generally refers to a carrier for administering therapeutic agents, such as antibodies or peptides, genes, and other therapeutic agents. This term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition and can be administered without causing excessive toxicity. For example, a pharmaceutically acceptable carrier can be distinguished from a nucleic acid vector used in genetic engineering to contain genes. Suitable carriers can be large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polyamino acids, amino acid copolymers, lipid aggregates, and inactivated viral particles. These carriers are well known to those skilled in the art. Pharmaceutically acceptable carriers in therapeutic compositions may include liquids such as water, saline, glycerol, and ethanol. These carriers may also contain excipients such as wetting agents or emulsifiers, pH buffers, etc.

[0104] In this application, the term "compound with antitumor activity" generally refers to a compound that has the ability to reduce the proliferation rate, viability, or metastatic activity of tumor cells. For example, antitumor activity may be demonstrated by a reduction in the growth rate of abnormal cells that appear during treatment, or by stabilization or shrinkage of tumor size, or by longer survival due to treatment compared to a control without treatment. Antitumor activity can be assessed using recognized in vitro or in vivo tumor models, such as xenograft models.

[0105] In some embodiments of the present invention, the bioactive molecule in the conjugate is a compound with specific antitumor activity, such as: radioactive isotopes, such as At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212, or Lu; metal complexes, such as platinum complexes (e.g., oxaliplatin) or gold complexes; glycopeptide antibiotics, such as bleomycin or bleomycin; topoisomerase inhibitors; drugs that interfere with DNA synthesis, such as methotrexate, 5-fluorouracil, cytarabine, gemcitabine, mercaptopurine, pentostatin, fludarabine, cladribine, or nelabine; drugs that act on structural proteins, such as microtubule inhibitors (e.g., vinblastine alkaloids, vincristine, paclitaxel, maytansine, aurestatin, tubulysin). B or eribulin, etc.); tumor signaling pathway inhibitors, such as serine / threonine kinase inhibitors, tyrosine kinase inhibitors, aspartate kinase inhibitors, or histidine kinase inhibitors, etc.; proteasome inhibitors; epigenetic-related target inhibitors; tumor angiogenesis inhibitors; cell cycle protein inhibitors.

[0106] In this application, the term "topoisomerase inhibitor" generally refers to compounds or derivatives thereof that include topoisomerase I inhibitors and topoisomerase II inhibitors. Examples of topoisomerase I inhibitors include, but are not limited to, camptothecin and its analogues; and topoisomerase II inhibitors (such as actinomycin D, doxorubicin, doxorubicin, daunorubicin, mitoxantrone, podophyllotoxin, or etoposide). A topoisomerase can be an enzyme that corrects the number of rings in DNA by cleaving phosphodiester bonds in one or both strands of DNA and then rewinding and sealing them.

[0107] In this application, the term "camptothecin analogue" generally refers to compounds that are structurally similar to or derived from camptothecin. For example, the structure of camptothecin can be described in CAS Registry No. 7689-03-4. For example, camptothecin analogues can refer to ixatecan (CAS Registry No. 171335-80-1) or beloteccan (CAS Registry No. 256411-32-2). The term "non-camptothecin topoisomerase I inhibitor" generally refers to heterocyclic molecules of the indolecarbazole class, indomethacinone class, benzo[a]phenanthridine class, and dibenzonaphthidone class that possess topoisomerase I inhibitory activity, primarily referring to Genz-644282 (CAS Registry No. 529488_28-6).

[0108] In this application, the term "effective amount" generally refers to the amount of a therapeutic agent that treats, alleviates, or prevents a target disease or condition, or the amount that exhibits a detectable therapeutic or preventative effect. The precise effective amount for a given subject depends on that subject's body size and health status, the nature and severity of the condition, and the choice of the therapeutic agent and / or combination of therapeutic agents administered. Therefore, it is useless to pre-specify an accurate effective amount. However, for a given condition, the effective amount can be determined using routine laboratory methods, and is readily apparent to a clinician.

[0109] The term "patient" includes both mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates such as chimpanzees and other apes and monkeys; farm animals such as cattle, horses, sheep, goats, and pigs; domesticated animals such as rabbits, dogs, and cats; laboratory animals, including rodents such as rats, mice, and guinea pigs, and including unborn (in utero) mammals. Examples of non-mammals include, but are not limited to, birds and fish.

[0110] The term “patient” includes confirmed patients, but the “patient” does not need to have any special status in the hospital, clinic or research facility (such as being a confirmed patient, research participant, etc.).

[0111] In this application, the term "hydrophobic chromatography" generally refers to an analytical technique based on the differences in hydrophobicity of substances.

[0112] In this application, the term "liquid chromatography-mass spectrometry" generally refers to an analytical method for identifying the components of a substance. For example, liquid chromatography-mass spectrometry can analyze the molecular weight of an analyte using liquid chromatography-mass spectrometry. Detailed Implementation Plan

[0113] In this document, “compounds of the present invention” refers to compounds of formula (I), (I-1), (I-2), (II), (II-1), (II-2), etc., their isotopic variants, tautomers or stereoisomers, or their scientifically or pharmaceutically acceptable salts.

[0114] In this document, compounds are named using standard nomenclature. For compounds with asymmetric centers, it should be understood (unless otherwise stated) that all optical isomers and mixtures thereof are included. Furthermore, unless otherwise specified, all isomers included in this invention may have carbon-carbon double bonds in the forms of Z and E. Regarding compounds existing in different tautomeric forms, a single compound is not limited to any particular tautomer, but is intended to encompass all tautomeric forms.

[0115] In one embodiment, the present invention relates to a compound of formula (I), or an isotopic variant, tautomer, or stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0116] in,

[0117] U is a linker that can react with thiol groups;

[0118] W1 is -W 1a -W 1b -;

[0119] W 1a Selected from chemical bonds, -(CH2) m24 -、-(OCH2CH2) n15 -or-(CH2CH2O) n16 -;

[0120] W 1b Selected from chemical bonds, -O-, -S-, -NR b -、-C(O)O-、-C(O)NR b -、-OC(O)-、-NR b -C(O)-, -S(O) p O-, -S(O) p NR b -、-OS(O) p -、-NR b -S(O) p -or-NR b -S(O) p NR b -;

[0121] Where p = 1 or 2;

[0122] L1 represents a chemical bond or -(CH2). m1 -(OCH2CH2) n1 -(CH2CH2O) n2 -(CH2) r1 -(L) q -(CH2) r2 -(OCH2CH2) n3 -(CH2CH2O) n4 -(CH2) m2 -;

[0123] Where -L- is selected from -O-, -NR b -、-C(O)NR b -、-C(O)O-、-NR b -C(O)-、-OC(O)-、-C 3- 8-cycloalkyl-, -3-8-membered heterocyclic-, -C 6-10 arylene- or -5-10 arylene-arylene;

[0124] Each m1, m2, m24, n1, n2, n3, n4, n15, n16, r1, and r2 is independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0125] q = 0, 1, or 2;

[0126] W2 is selected from chemical bonds, -O-, -S-, and -NR. b -or -C(O)-;

[0127] L2 is selected from the following amino acid residues or oligopeptide residues consisting of 2 to 10 amino acids, wherein the amino acids are selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, and wherein the amino acids are optionally substituted by 1, 2, 3, 4, 5, or 6 R4 residues, and at least one amino acid is replaced by R4. H replace;

[0128] The N-terminus of the amino acid residue or oligopeptide residue is linked to W2, and the C-terminus is linked to L3;

[0129] R H It is -H1-H2-NR2R3;

[0130] Wherein, H1 is selected from chemical bonds, -O-, -S-, -NR1-, -C(O)-, -S(O)- and -S(O)2-;

[0131] H2 is -(CH2) a - where 1, 2 or 3 methylene units are optionally and independently replaced by -O-, -S- or -NR1-;

[0132] a = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0133] R1 is selected from H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups;

[0134] R2 and R3 are each independently selected from H and C. 1-6 Alkyl, C 1-6 The alkyl halogroup and the hydrophilic polyhydroxy alcohol group, or polyethylene glycol or a structural variant thereof, and at least one of R2 and R3 is a hydrophilic polyhydroxy alcohol group;

[0135] R4 is independently selected from D, halogens, NO2, and -OR. a -NR b R cC 1-6 Alkyl, C 1-6 Halogenated alkyl groups, polyethylene glycol, polysarcosine, pentose sugars, hexose sugars, sulfonic acid groups, methanesulfonyl groups, phosphoric acid groups, phosphite groups, quaternary ammonium salts, or groups selected from the following:

[0136] L3 is selected from chemical bonds or the following structures:

[0137] NH is connected to L2, and C(O) is connected to D;

[0138] R5 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl or C 1-6 Halogenated alkyl groups;

[0139] t = 0, 1, 2, 3 or 4;

[0140] R6 is selected from H,

[0141] D is the active compound, selected from drugs, cytotoxins, detection reagents, diagnostic reagents, or targeting carriers;

[0142] R a R b and R c Independently selected from H and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-10 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 aryl or 5-10 heteroaryl; or R b and R c Together with the N atoms they are connected to, they form 3-10 membered heterocyclic groups;

[0143] The aforementioned groups may optionally be substituted with one or more deuterium groups, up to and including complete deuteration.

[0144] In another embodiment, the compound of the present invention further has the structure of formula (I-1) or formula (I-2):

[0145] in,

[0146] b = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably b = 0, 1, 2, 3, 4, 5 or 6, preferably b = 0, 1, 2 or 3, preferably b = 2;

[0147] The remaining variables are as defined in this invention.

[0148] In another aspect, the present invention provides a compound of formula (II), or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof:

[0149] in,

[0150] A is a targeted molecule;

[0151] U' is a group formed after the reaction of the linker and the thiol group;

[0152] x = 1, 2, 3, 4, 5, 6, 7 or 8;

[0153] W1 is -W 1a -W 1b -;

[0154] W 1a Selected from chemical bonds, -(CH2) m24 -、-(OCH2CH2) n15 -or-(CH2CH2O) n16 -;

[0155] W 1b Selected from chemical bonds, -O-, -S-, -NR b -、-C(O)O-、-C(O)NR b -、-OC(O)-、-NR b -C(O)-, -S(O) p O-, -S(O) p NR b -、-OS(O) p -、-NR b -S(O) p -or-NR b -S(O) p NR b -;

[0156] Where p = 1 or 2;

[0157] L1 represents a chemical bond or -(CH2). m1 -(OCH2CH2) n1 -(CH2CH2O) n2 -(CH2) r1 -(L)q -(CH2) r2 -(OCH2CH2) n3 -(CH2CH2O) n4 -(CH2) m2 -;

[0158] Where -L- is selected from -O-, -NR b -、-C(O)NR b -、-C(O)O-、-NR b -C(O)-、-OC(O)-、-C 3- 8-cycloalkyl-, -3-8-membered heterocyclic-, -C 6-10 arylene- or -5-10 arylene-arylene;

[0159] Each m1, m2, m24, n1, n2, n3, n4, n15, n16, r1, and r2 is independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0160] q = 0, 1, or 2;

[0161] W2 is selected from chemical bonds, -O-, -S-, and -NR. b -or -C(O)-;

[0162] L2 is selected from the following amino acid residues or oligopeptide residues consisting of 2 to 10 amino acids, wherein the amino acids are selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, and wherein the amino acids are optionally substituted by 1, 2, 3, 4, 5, or 6 R4 residues, and at least one amino acid is replaced by R4. H replace;

[0163] The N-terminus of the amino acid residue or oligopeptide residue is linked to W2, and the C-terminus is linked to L3;

[0164] R H It is -H1-H2-NR2R3;

[0165] Wherein, H1 is selected from chemical bonds, -O-, -S-, -NR1-, -C(O)-, -S(O)- and -S(O)2-;

[0166] H2 is -(CH2) a - where 1, 2 or 3 methylene units are optionally and independently replaced by -O-, -S- or -NR1-;

[0167] a = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0168] R1 is selected from H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups;

[0169] R2 and R3 are each independently selected from H and C. 1-6 Alkyl, C 1-6 The alkyl halogroup and the hydrophilic polyhydroxy alcohol group, or polyethylene glycol or a structural variant thereof, and at least one of R2 and R3 is a hydrophilic polyhydroxy alcohol group;

[0170] R4 is independently selected from D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl, C 1-6 Halogenated alkyl groups, polyethylene glycol, polysarcosine, pentose sugars, hexose sugars, sulfonic acid groups, methanesulfonyl groups, phosphoric acid groups, phosphite groups, quaternary ammonium salts, or groups selected from the following:

[0171] L3 is selected from chemical bonds or the following structures:

[0172] NH is connected to L2, and C(O) is connected to D;

[0173] R5 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl or C 1-6 Halogenated alkyl groups;

[0174] t = 0, 1, 2, 3 or 4;

[0175] R6 is selected from H,

[0176] D is the active compound, selected from drugs, cytotoxins, detection reagents, diagnostic reagents, or targeting carriers;

[0177] R a R b and R c Independently selected from H and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-10 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 aryl or 5-10 heteroaryl; or R band R c Together with the N atoms they are connected to, they form 3-10 membered heterocyclic groups;

[0178] The aforementioned groups may optionally be substituted with one or more deuterium groups, up to and including complete deuteration.

[0179] In another embodiment, the compound of the present invention further has the structure of formula (II-1) or formula (II-2):

[0180] The variables are as defined in this invention.

[0181] In the compounds of this invention, each group can be defined as follows.

[0182] A

[0183] In one embodiment, A is a targeting molecule; in one specific embodiment, A is selected from proteins, antibodies, antibody fragments, fusion proteins, peptides, enzymes, and small molecules; in one specific embodiment, A is a protein; in another specific embodiment, A is an antibody, preferably a monoclonal antibody, such as a monospecific monoclonal antibody and a bispecific monoclonal antibody; in another specific embodiment, A is an IgG antibody targeting tumor-associated antigens; in one specific embodiment, A is an antibody fragment; in one specific embodiment, A is a fusion protein; in one specific embodiment, A is a peptide; in one specific embodiment, A is an enzyme; in one specific embodiment, A is a small molecule.

[0184] x

[0185] In one embodiment, x = 1; in another embodiment, x = 2; in another embodiment, x = 3; in another embodiment, x = 4; in another embodiment, x = 5; in another embodiment, x = 6; in another embodiment, x = 7; in another embodiment, x = 8; in another embodiment, x = 2, 3, 4, 5, 6, 7 or 8; in another embodiment, x = 2, 4, 6 or 8; in another embodiment, x = 4, 6 or 8; in another embodiment, x = 4 or 8.

[0186] U

[0187] In one embodiment, U is a linker capable of reacting with a thiol group; in another embodiment, U is a single-reactive linker capable of reacting with a thiol group; in yet another embodiment, U is a bridged double-reactive linker capable of reacting with a thiol group; in yet another embodiment, U is... In another implementation, U is In another implementation, U is In another implementation, U is In another implementation, U is In another implementation, U is

[0188] In one specific embodiment, U is selected from single-reactive connectors and bridging double-reactive connectors capable of reacting with thiol groups; in another specific embodiment, U is selected from... In another specific embodiment, U is selected from In another specific embodiment, U is selected from

[0189] In one implementation, R9 is C 1-6 Alkyl; in another embodiment, R9 is C 1-6 Halogenated alkyl; in another embodiment, R9 is C 1-4 Alkyl; in another embodiment, R9 is C 1-4 Halogenated alkyl; in another embodiment, R9 is methyl.

[0190] In one specific implementation, R9 is independently selected from C 1-6 Alkyl or C 1-6 Halogenated alkyl group; in another specific embodiment, R9 is independently selected from C. 1-4 Alkyl or C 1-4 Halogenated alkyl groups.

[0191] In one embodiment, X is a halogen; in another embodiment, X is Cl; in yet another embodiment, X is Br; and in yet another embodiment, X is I.

[0192] In one specific implementation, X is Cl, Br, or I.

[0193] U'

[0194] In one embodiment, U' is a group formed after the linker reacts with a thiol group; in another embodiment, U' is... In another implementation, U' is In another implementation, U' is In another implementation, U' is In another implementation, U' is In another implementation, U' is In another embodiment, the carbon atom at the # end is linked to the sulfur atom in the cysteine ​​residue of the targeted molecule A via a thioether bond.

[0195] In one specific implementation, U' is selected from: In another specific embodiment, U' is selected from In another specific embodiment, U' is selected from The carbon atom at the # end is linked to the sulfur atom in the cysteine ​​residue of the targeted molecule A through a thioether bond.

[0196] W1

[0197] In one implementation, W1 is -W 1a -W 1b -

[0198] In one implementation, W 1a For chemical bonds; in another embodiment, W 1a -(CH2) m24 -; In another implementation, W 1a -(OCH2CH2) n15 -; In another implementation, W 1a -(CH2CH2O) n16 -

[0199] In one implementation, W 1b For chemical bonds; in another embodiment, W 1b For -O-; in another implementation, W 1b For -S-; in another embodiment, W 1b For -NR b -; In another implementation, W 1b For -C(O)O-; in another embodiment, W 1b -C(O)NR b -; In another implementation, W 1b For -OC(O)-; in another embodiment, W 1b For -NR b -C(O)-; In another embodiment, W 1b For -S(O) p O-; in another implementation, W 1b For -S(O) p NR b -; In another implementation, W 1b For -OS(O) p -; In another implementation, W 1b For -NR b -S(O) p-; In another implementation, W 1b For -NR b -S(O) p NR b -;

[0200] In one embodiment, p = 1; in another embodiment, p = 2.

[0201] In one specific implementation, W 1a Selected from chemical bonds, -(CH2) m24 -、-(OCH2CH2) n15 -or-(CH2CH2O) n16 -; In another specific embodiment, W 1a Selected from chemical bonds and -(CH2) m24 -

[0202] In one specific implementation, W 1b Selected from -C(O)O-, -C(O)NR b -、-OC(O)- or -NR b -C(O)-; In another specific embodiment, W 1b Selected from -C(O)O- or -C(O)NR b -

[0203] L1

[0204] In one embodiment, L1 is a chemical bond; in another embodiment, L1 is -(CH2). m1 -(OCH2CH2) n1 -(CH2CH2O) n2 -(CH2) r1 -(L) q -(CH2) r2 -(OCH2CH2) n3 -(CH2CH2O) n4 -(CH2) m2 -

[0205] In another implementation, L1 is -(CH2). m1 -(CH2CH2O) n1 -(CH2) r1 -L-(CH2) r2 -(CH2CH2O) n2 -(CH2) m2 -; In another embodiment, L1 is -(CH2). m3 -(OCH2CH2) n3 -(CH2) r3-L-(CH2) r4 -(OCH2CH2) n4 -(CH2) m4 -

[0206] In another embodiment, L1 is -(CH2CH2O). n5 -(CH2) r5 -L-(CH2) m5 -; In another embodiment, L1 is -(OCH2CH2) n6 -(CH2) r6 -L-(CH2) m6 -; In another embodiment, L1 is -(CH2). m7 -L-(CH2CH2O) n7 -(CH2) r7 -; In another embodiment, L1 is -(CH2). m8 -L-(OCH2CH2) n8 -(CH2) r8 -

[0207] In another implementation, L1 is -(CH2). m9 -(CH2CH2O) n9 -(CH2) r9 -; In another embodiment, L1 is -(CH2). m10 -(OCH2CH2) n10 -(CH2) r10 -

[0208] In another embodiment, L1 is -(CH2CH2O). n11 -(CH2) m11 -; In another embodiment, L1 is -(CH2). m12 -(CH2CH2O) n12 -; In another embodiment, L1 is -(OCH2CH2) n13 -(CH2) m13 -; In another embodiment, L1 is -(CH2). m14 -(OCH2CH2) n14 -

[0209] In another implementation, L1 is -(CH2). m15 -O-(CH2) m16 -; In another embodiment, L1 is -(CH2). m17 -O-、-(CH2) m18 -NH-; in another embodiment, L1 is -O-(CH2).m19 -; In another implementation, L1 is -NR b -(CH2) m20 -; In another embodiment, L1 is -(CH2). m21 -; In another embodiment, L1 is -L-; In another embodiment, L1 is -(CH2) m22 -L-; In another embodiment, L1 is -L-(CH2). m23 -

[0210] In another embodiment, L1 is -(CH2CH2O). n11 -(CH2) m11 -, preferably -(CH2CH2O) n11 -; In another embodiment, L1 is -(CH2). m21 -

[0211] In one specific implementation, -L- is -O-; in another specific implementation, -L- is -NR. b -; In another specific embodiment, -L- is -C(O)NR b -; In another specific embodiment, -L- is -C(O)O-; In another specific embodiment, -L- is -NR b -C(O)-; In another specific embodiment, -L- is -OC(O)-; In another specific embodiment, -L- is -C 3-8 Cycloalkylene-; in another embodiment, -L- is a -3-8 membered heterocyclic alkylene-; in another embodiment, -L- is a -C 6-10 -L-; in another specific embodiment, -L- is a -5-10-membered heteroaryl group.

[0212] In one embodiment, q = 0; in another embodiment, q = 1; in yet another embodiment, q = 2.

[0213] m, n and r

[0214] In one embodiment, m = 0; in another embodiment, m = 1; in another embodiment, m = 2; in another embodiment, m = 3; in another embodiment, m = 4; in another embodiment, m = 5; in another embodiment, m = 6; in another embodiment, m = 7; in another embodiment, m = 8; in another embodiment, m = 9; in another embodiment, m = 10.

[0215] Where m can be m1, m2, m3, m4, m5, m6, m7, m8, m9, m10, m11, m12, m13, m14, m15, m16, m17, m18, m19, m20, m21, m22, m23, m24.

[0216] In one embodiment, n = 0; in another embodiment, n = 1; in another embodiment, n = 2; in another embodiment, n = 3; in another embodiment, n = 4; in another embodiment, n = 5; in another embodiment, n = 6; in another embodiment, n = 7; in another embodiment, n = 8; in another embodiment, n = 9; in another embodiment, n = 10.

[0217] Where n can be n1, n2, n3, n4, n5, n6, n7, n8, n9, n10, n11, n12, n13, n14, n15, n16.

[0218] In one embodiment, r = 0; in another embodiment, r = 1; in another embodiment, r = 2; in another embodiment, r = 3; in another embodiment, r = 4; in another embodiment, r = 5; in another embodiment, r = 6; in another embodiment, r = 7; in another embodiment, r = 8; in another embodiment, r = 9; in another embodiment, r = 10.

[0219] Where r can be r1, r2, r3, r4, r5, r6, r7, r8, r9, or r10.

[0220] In another specific embodiment, m1, m2, m3, m4, m5, m6, m7, m8, m9, m10, m11, m12, m13, m14, m15, m16, m17, m18, m19, m20, m21, m22, m23, and m24 are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, preferably 0, 1, 2, 3, 4, 5, or 6; n1, n2, n3, n4, n5, n6, n7, n8, n9, n10, n11, n12, n13, n14, n15, and n16 are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, preferably 0, 1, 2, 3, 4, 5, or 6; r1, r2, r3, r4, r5, r6, r7, r8, r9, and r10 are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, preferably 0, 1, 2, 3, 4, 5, or 6.

[0221] W2

[0222] In one embodiment, W2 is a chemical bond; in another embodiment, W2 is -O-; in yet another embodiment, W2 is -S-; in still another embodiment, W2 is -NR. b -; In another implementation, W2 is -C(O)-.

[0223] L2

[0224] In one embodiment, L2 is selected from the following amino acid residues or oligopeptide residues consisting of 2 to 10 amino acids, wherein the amino acids are selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, and wherein the amino acids are optionally substituted by 1, 2, 3, 4, 5, or 6 R4 residues, and at least one amino acid is substituted by R4. H Substitution; in another embodiment, L2 is selected from the following amino acid residues or oligopeptide residues consisting of 2 to 5 amino acids, wherein the amino acids are selected from phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, and wherein the amino acids are optionally substituted by 1, 2, 3, or 4 R4 residues, and one of the amino acids is substituted by 1 R4 residue. H Substitution; in another embodiment, L2 is selected from dipeptide, tripeptide, or tetrapeptide (preferably dipeptide or tripeptide) residues composed of the following amino acids, wherein the amino acids are selected from phenylalanine, isoleucine, leucine, valine, alanine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, citrulline, aspartic acid, and glycine, and wherein the amino acids are optionally substituted by 1, 2, 3, or 4 R4 residues, and one of the amino acids is substituted by 1 R4 residue. H Substitution; in another embodiment, L2 is selected from valine-glutamic acid, valine-glutamine, valine-aspartic acid, valine-asparagine, glutamic acid-valine-alanine, glutamine-valine-alanine, aspartic acid-valine-alanine, and asparagine-valine-alanine, which is optionally substituted with 1, 2, 3, or 4 R4s, and one of the amino acids is substituted with 1 R4. H replace.

[0225] In one embodiment, the N-terminus of the amino acid residue or oligopeptide residue is linked to W2, and the C-terminus is linked to L3.

[0226] In one implementation, RH The substituted amino acid is selected from glutamic acid, glutamine, aspartic acid, and asparagine; in another embodiment, R... H The substituted amino acid is selected from glutamic acid and glutamine; in another embodiment, it is R H The substituted amino acid is glutamic acid.

[0227] In one embodiment, L2 is -P1-AA1-, where AA1 is connected to L3; in another embodiment, L2 is -AA2-P1-, where AA2 is connected to W2.

[0228] In one embodiment, P1 is independently selected from glutamic acid, glutamine, aspartic acid, and asparagine, and is controlled by one R H replace.

[0229] In one embodiment, AA1 is selected from the following amino acid residues or oligopeptide residues consisting of 2-3 (preferably 2) or fewer amino acids; wherein the amino acid is selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably valine, alanine, leucine, and isoleucine, preferably valine and alanine, and preferably valine-alanine; and the amino acid is optionally substituted by 1, 2, 3, 4, 5, or 6 (preferably 1, 2, 3, or 4) R4 residues;

[0230] In one embodiment, AA2 is selected from the following amino acid residues or oligopeptide residues consisting of 2-3 or fewer amino acids; wherein the amino acid is selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably the following amino acid residues: valine, alanine, leucine, and isoleucine, preferably valine; and the amino acid is optionally substituted by 1, 2, 3, 4, 5, or 6 (preferably 1, 2, 3, or 4) R4 residues.

[0231] R H

[0232] In one implementation, R H It is -H1-H2-NR2R3.

[0233] In one embodiment, H1 is a chemical bond; in another embodiment, H1 is -O-; in another embodiment, H1 is -S-; in another embodiment, H1 is -NR1-; in another embodiment, H1 is -C(O)-; in another embodiment, H1 is -S(O)-; in another embodiment, H1 is -S(O)2-.

[0234] In one embodiment, H1 is selected from chemical bonds, -O-, -S-, -NR1-, -C(O)-, -S(O)-, and -S(O)2-; in another embodiment, H1 is selected from chemical bonds, -O-, -S-, and -NR1-; in yet another embodiment, H1 is selected from chemical bonds, -O-, and -NR1-; and in yet another embodiment, H1 is selected from chemical bonds and -NR1-.

[0235] In one embodiment, R1 is H; in another embodiment, R1 is C. 1-6 Alkyl; in another specific embodiment, R1 is C 1-6 Halogenated alkyl; in another specific embodiment, R1 is C 1-4 Alkyl; in another specific embodiment, R1 is C 1-4 Halogenated alkyl groups.

[0236] In one implementation, H2 is -(CH2). a - where 1, 2 or 3 methylene units are optionally and independently replaced by -O-, -S- or -NR1- (preferably -O-).

[0237] In one embodiment, a = 0; in another embodiment, a = 1; in another embodiment, a = 2; in another embodiment, a = 3; in another embodiment, a = 4; in another embodiment, a = 5; in another embodiment, a = 6; in another embodiment, a = 7; in another embodiment, a = 8; in another embodiment, a = 9; in another embodiment, a = 10; in another embodiment, a = 1, 2, 3, 4, 5 or 6; in another embodiment, a = 1, 2, 3 or 4; in another embodiment, a = 1 or 2.

[0238] R2 and R3

[0239] In one implementation, R2 is H; in another implementation, R2 is C. 1-6 Alkyl; in another embodiment, R2 is C 1-6Halogenated alkyl group; in another embodiment, R2 is a hydrophilic group of a polyhydroxy alcohol; in another embodiment, R2 is polyethylene glycol or a structural variant thereof.

[0240] In one embodiment, R3 is H; in another embodiment, R3 is C. 1-6 Alkyl; in another embodiment, R3 is C 1-6 Halogenated alkyl group; in another embodiment, R3 is a hydrophilic group of a polyhydroxy alcohol; in another embodiment, R3 is polyethylene glycol or a structural variant thereof.

[0241] In one embodiment, at least one of R2 and R3 is a hydrophilic group of a polyhydroxy alcohol.

[0242] In a more specific embodiment, the hydrophilic group of the polyhydroxy alcohol has the following structure: -X1(CR7OH)zX2R8.

[0243] In one embodiment, X1 is a chemical bond; in another embodiment, X1 is a C 1-6 Alkylene, preferably C 1-4 Alkylene, preferably C 1-2 Alkylene, such as methylene; in another embodiment, X1 is -NR1-; in another embodiment, X1 is -C(O)-; in another embodiment, X1 is -S(O)-; in another embodiment, X1 is -S(O)2-.

[0244] In one embodiment, X2 is a chemical bond; in another embodiment, X2 is a C bond. 1-6 Alkylene, preferably C 1-4 Alkylene, preferably C 1-2 Alkylene, such as methylene; in another embodiment, X2 is -NR1-; in another embodiment, X2 is -C(O)-; in another embodiment, X2 is -S(O)-; in another embodiment, X2 is -S(O)2-.

[0245] In a more specific embodiment, X1 and X2 are independently selected from chemical bonds, C 1-6 Alkylene, -NR1-, -C(O)-, -S(O)-, and -S(O)2-; in another more specific embodiment, X1 and X2 are independently selected from chemical bonds, C 1-6 Alkylene (preferably C) 1-4 Alkylene, preferably C 1-2 Alkylene), -NR1- and -C(O)-.

[0246] In one implementation, R7 is H; in another implementation, R7 is C. 1-6Alkyl; in another embodiment, R7 is C 1-6 Halogenated alkyl; in another embodiment, R7 is C 1-4 Alkyl; in another embodiment, R7 is C 1-4 Halogenated alkyl groups.

[0247] In a more specific implementation, R7 is independently selected from H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl group; in another, more specific embodiment, R7 is independently selected from H, C 1-4 Alkyl or C 1-4 Halogenated alkyl groups.

[0248] In one implementation, R8 is H; in another implementation, R8 is CN; in yet another implementation, R8 is -OR a In another implementation, R8 is -NR b R c In another embodiment, R8 is C 1-6 Alkyl; in another embodiment, R8 is C 1-6 Halogenated alkyl groups.

[0249] In a more specific implementation, R8 is independently selected from H, CN, and -OR. a -NR b R c C 1-6 Alkyl or C 1-6 Halogenated alkyl group; in a more specific embodiment, R8 is independently selected from H, -OR a C 1-6 Alkyl or C 1-6 Halogenated alkyl groups.

[0250] In one embodiment, z = 0; in another embodiment, z = 1; in another embodiment, z = 2; in another embodiment, z = 3; in another embodiment, z = 4; in another embodiment, z = 5; in another embodiment, z = 6; in another embodiment, z = 7; in another embodiment, z = 8; in another embodiment, z = 9; in another embodiment, z = 10; in another embodiment, z = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; in another embodiment, z = 3, 4, 5 or 6.

[0251] In a more specific embodiment, the structure of the hydrophilic group of the polyhydroxy alcohol is as follows: Preferred In another, more specific embodiment, the structure of the hydrophilic group of the polyhydroxy alcohol is as follows: Preferred

[0252] R4

[0253] In one embodiment, R4 is D; in another embodiment, R4 is a halogen; in yet another embodiment, R4 is NO2; in still another embodiment, R4 is -OR. a In another implementation, R4 is -NR b R c In another embodiment, R4 is C 1-6 Alkyl; in another embodiment, R4 is C 1-6 Halogenated alkyl group; in another embodiment, R4 is polyethylene glycol; in another embodiment, R4 is polysarcosine; in another embodiment, R4 is a pentose sugar; in another embodiment, R4 is a hexose sugar; in another embodiment, R4 is a sulfonic acid group; in another embodiment, R4 is a methanesulfonyl group; in another embodiment, R4 is a phosphoric acid group; in another embodiment, R4 is a phosphorous acid group; in another embodiment, R4 is a quaternary ammonium salt; in another embodiment, R4 is... In another implementation, R4 is In another implementation, R4 is In another implementation, R4 is In another implementation, R4 is In another implementation, R4 is In another implementation, R4 is In another implementation, R4 is In another implementation, R4 is In another implementation, R4 is In another implementation, R4 is In another implementation, R4 is In another implementation, R4 is

[0254] In a more specific embodiment, R4 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl, C 1-6 Halogenated alkyl groups, polyethylene glycol, polysarcosine, pentose sugars, hexose sugars, sulfonic acid groups, methanesulfonyl groups, phosphoric acid groups, phosphite groups, quaternary ammonium salts, or groups selected from the following:

[0255] In a more specific embodiment, R4 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0256] L3

[0257] In one embodiment, L3 is a chemical bond; in another embodiment, L3 is... Preferred Preferred In another implementation, L3 is In another implementation, L3 is In one implementation, NH in L3 is connected to L2, and C(O) is connected to D.

[0258] In a more specific implementation, L3 is selected from chemical bonds or the following structures: In another, more specific embodiment, L3 is selected from chemical bonds or In another, more specific embodiment, L3 is selected from chemical bonds or

[0259] R5

[0260] In one embodiment, R5 is H; in another embodiment, R5 is D; in yet another embodiment, R5 is a halogen; in another embodiment, R5 is NO2; in yet another embodiment, R5 is -OR a In another implementation, R5 is -NR b R c In another embodiment, R5 is C. 1- 6-alkyl; in another embodiment, R5 is C 1-6 Halogenated alkyl groups.

[0261] In a more specific embodiment, R5 is independently selected from H, D, halogen, C. 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0262] t

[0263] In one implementation, t = 0; in another implementation, t = 1; in another implementation, t = 2; in another implementation, t = 3; in another implementation, t = 4.

[0264] R6

[0265] In one implementation, R6 is H; in another implementation, R6 is In another implementation, R6 is

[0266] In a more specific implementation, R6 is selected from H,

[0267] D

[0268] In one embodiment, D is an active compound; in another embodiment, D is a drug; in another embodiment, D is a cytotoxin; in another embodiment, D is a detection reagent; in another embodiment, D is a diagnostic reagent; in another embodiment, D is a targeting carrier.

[0269] R a R b and R c

[0270] In one implementation, R a H; in another embodiment, R a C 1-6 Alkyl; in another embodiment, R a C 1-6 Halogenated alkyl; in another embodiment, R a C 2-6 alkenyl; in another embodiment, R a C 2-6 Alkyne group; in another embodiment, R a C 3-10 cycloalkyl; in another embodiment, R a It is a 3-10 member heterocyclic group; in another embodiment, R a C 6-10 aryl; in another embodiment, R a It consists of 5-10 heteroaryl compounds.

[0271] In one implementation, R b H; in another embodiment, R b C 1-6 Alkyl; in another embodiment, R b C1-6 Halogenated alkyl; in another embodiment, R b C 2-6 alkenyl; in another embodiment, R b C 2-6 Alkyne group; in another embodiment, R b C 3-10 cycloalkyl; in another embodiment, R b It is a 3-10 member heterocyclic group; in another embodiment, R b C 6-10 aryl; in another embodiment, R b It consists of 5-10 heteroaryl compounds.

[0272] In one implementation, R c H; in another embodiment, R c C 1-6 Alkyl; in another embodiment, R c C 1-6 Halogenated alkyl; in another embodiment, R c C 2-6 alkenyl; in another embodiment, R c C 2-6 Alkyne group; in another embodiment, R c C 3-10 cycloalkyl; in another embodiment, R c It is a 3-10 member heterocyclic group; in another embodiment, R c C 6-10 aryl; in another embodiment, R c It consists of 5-10 heteroaryl compounds.

[0273] In one implementation, R b and R c Together with the atoms they are connected to form 3-10 membered heterocyclic groups, preferably 5-7 membered heterocyclic groups; in another embodiment, R b R c And the atoms they connect do not form rings.

[0274] In a more specific implementation, R a R b and R c Each is independently selected from H and C. 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0275] Chiral centers *1 and *2

[0276] In one embodiment, *1 is an (S) configuration; in another embodiment, *1 is an (R) configuration; in yet another embodiment, *1 is a racemic form.

[0277] In one embodiment, *2 is an (S) configuration; in another embodiment, *2 is an (R) configuration; in yet another embodiment, *2 is a racemic form.

[0278] b

[0279] In one embodiment, b = 0; in another embodiment, b = 1; in another embodiment, b = 2; in another embodiment, b = 3; in another embodiment, b = 4; in another embodiment, b = 5; in another embodiment, b = 6; in another embodiment, b = 7; in another embodiment, b = 8; in another embodiment, b = 9; in another embodiment, b = 10; in another embodiment, b = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; in another embodiment, b = 0, 1, 2, 3, 4, 5 or 6; in another embodiment, b = 0, 1, 2 or 3.

[0280] Any technical solution or any combination thereof in any of the above specific embodiments can be combined with any technical solution or any combination thereof in other specific embodiments. For example, any technical solution or any combination thereof of U or U' can be combined with A, x, W1, L1, m, n, r, W2, L2, R H , R2, R3, R4, L3, R5, t, R6, D, R a R b R c This invention may combine any of the technical solutions, such as *1, *2, and b, or any combination thereof. The invention aims to include combinations of all these technical solutions; however, due to space limitations, they will not be listed individually.

[0281] In a more specific embodiment, the present invention provides a compound of formula (I), or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof:

[0282] in,

[0283] U is a linker that can react with thiol groups;

[0284] W1 is -W 1a -W 1b -;

[0285] W 1a Selected from chemical bonds, -(CH2) m24-、-(OCH2CH2) n15 -or-(CH2CH2O) n16 -;

[0286] W 1b Selected from chemical bonds, -O-, -S-, -NR b -、-C(O)O-、-C(O)NR b -、-OC(O)-、-NR b -C(O)-, -S(O) p O-, -S(O) p NR b -、-OS(O) p -、-NR b -S(O) p -or-NR b -S(O) p NR b -;

[0287] Where p = 1 or 2;

[0288] L1 represents a chemical bond or -(CH2). m1 -(OCH2CH2) n1 -(CH2CH2O) n2 -(CH2) r1 -(L) q -(CH2) r2 -(OCH2CH2) n3 -(CH2CH2O) n4 -(CH2) m2 -;

[0289] Where -L- is selected from -O-, -NR b -、-C(O)NR b -、-C(O)O-、-NR b -C(O)-、-OC(O)-、-C 3- 8-cycloalkyl-, -3-8-membered heterocyclic-, -C 6-10 arylene- or -5-10 arylene-arylene;

[0290] Each m1, m2, m24, n1, n2, n3, n4, n15, n16, r1, and r2 is independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0291] q = 0, 1, or 2;

[0292] W2 is selected from chemical bonds, -O-, -S-, and -NR. b -or -C(O)-;

[0293] L2 is selected from the following amino acid residues or oligopeptide residues consisting of 2 to 10 amino acids, wherein the amino acids are selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, and wherein the amino acids are optionally substituted by 1, 2, 3, 4, 5, or 6 R4 residues, and at least one amino acid is replaced by R4. H replace;

[0294] The N-terminus of the amino acid residue or oligopeptide residue is linked to W2, and the C-terminus is linked to L3;

[0295] R H It is -H1-H2-NR2R3;

[0296] Wherein, H1 is selected from chemical bonds, -O-, -S-, -NR1-, -C(O)-, -S(O)- and -S(O)2-;

[0297] H2 is -(CH2) a - where 1, 2 or 3 methylene units are optionally and independently replaced by -O-, -S- or -NR1-;

[0298] a = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0299] R1 is selected from H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups;

[0300] R2 and R3 are each independently selected from H and C. 1-6 Alkyl, C 1-6 The alkyl halogroup and the hydrophilic polyhydroxy alcohol group, or polyethylene glycol or a structural variant thereof, and at least one of R2 and R3 is a hydrophilic polyhydroxy alcohol group;

[0301] R4 is independently selected from D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl, C 1-6 Halogenated alkyl groups, polyethylene glycol, polysarcosine, pentose sugars, hexose sugars, sulfonic acid groups, methanesulfonyl groups, phosphoric acid groups, phosphite groups, quaternary ammonium salts, or groups selected from the following:

[0302] L3 is selected from chemical bonds or the following structures:

[0303] NH is connected to L2, and C(O) is connected to D;

[0304] R5 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl or C 1-6 Halogenated alkyl groups;

[0305] t = 0, 1, 2, 3 or 4;

[0306] R6 is selected from H,

[0307] D is the active compound, selected from drugs, cytotoxins, detection reagents, diagnostic reagents, or targeting carriers;

[0308] R a R b and R c Independently selected from H and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-10 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 aryl or 5-10 heteroaryl; or R b and R c Together with the N atoms they are connected to, they form 3-10 membered heterocyclic groups;

[0309] The aforementioned groups may optionally be substituted with one or more deuterium groups, up to and including complete deuteration.

[0310] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein U is selected from single-reactive linkers and bridged double-reactive linkers capable of reacting with thiol groups; preferably selected from: Preferred selection Preferred Among them, R9 is independently selected from C 1-6 Alkyl or C 1-6 Halogenated alkyl groups, preferably C 1-4 Alkyl or C 1-4 The alkyl group is haloalkyl, preferably methyl; X is a halogen, preferably Cl, Br or I, preferably I.

[0311] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein W1 is -W 1a -W 1b -;

[0312] W 1a Selected from chemical bonds, -(CH2) m24 -、-(OCH2CH2) n15 -or-(CH2CH2O) n16 -, preferably chemical bonds and -(CH2) m24 -; Preferred chemical bonds;

[0313] W 1b Selected from -C(O)O-, -C(O)NR b -、-OC(O)- or -NR b -C(O)-, preferably -C(O)O- or -C(O)NR b -;

[0314] Wherein m24, n15, n15 are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 1, 2, 3, 4, 5 or 6.

[0315] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein...

[0316] L1 is selected from chemical bonds, -(CH2) m1 -(CH2CH2O) n1 -(CH2) r1 -L-(CH2) r2 -(CH2CH2O) n2 -(CH2) m2 -or-(CH2) m3 -(OCH2CH2) n3 -(CH2) r3 -L-(CH2) r4 -(OCH2CH2) n4 -(CH2) m4 -;

[0317] Preferably, L1 is selected from chemical bonds, -(CH2CH2O). n5 -(CH2) r5 -L-(CH2) m5 -、-(OCH2CH2)n6 -(CH2) r6 -L-(CH2) m6 -、-(CH2) m7 -L-(CH2CH2O) n7 -(CH2) r7 -or-(CH2) m8 -L-(OCH2CH2) n8 -(CH2) r8 -;

[0318] Preferably, L1 is selected from chemical bonds, -(CH2). m9 -(CH2CH2O) n9 -(CH2) r9 -or-(CH2) m10 -(OCH2CH2) n10 -(CH2) r10 -;

[0319] Preferably, L1 is selected from chemical bonds, -(CH2CH2O). n11 -(CH2) m11 -、-(CH2) m12 -(CH2CH2O) n12 -、-(OCH2CH2) n13 -(CH2) m13 -or-(CH2) m14 -(OCH2CH2) n14 -;

[0320] Preferably, L1 is selected from chemical bonds, -(CH2). m15 -O-(CH2) m16 -、-(CH2) m17 -O-、-(CH2) m18 -NH-, -O-(CH2) m19 -or-NR b -(CH2) m20 - Preferably, L1 is selected from chemical bonds, -(CH2). m21 -、-L-、-(CH2) m22 -L- or -L-(CH2) m23 -;

[0321] Preferably, L1 is selected from chemical bonds, -(CH2CH2O). n11 -(CH2) m11 -or-(CH2) m21 -;

[0322] Where m1, m2, m3, m4, m5, m6, m7, m8, m9, m10, m11, m12, m13, m14, m15, m16, m17, m18, m19, m20, m21, m22, and m23 are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0323] n1, n2, n3, n4, n5, n6, n7, n8, n9, n10, n11, n12, n13, n14 are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0324] r1, r2, r3, r4, r5, r6, r7, r8, r9, r10 are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0325] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein -L- is selected from -C(O)NR b -、-C(O)O-、-NR b -C(O)- or -OC(O)-.

[0326] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic compound or tautomer, or a pharmaceutically acceptable salt thereof, wherein W2 is selected from chemical bonds or -C(O)-.

[0327] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein...

[0328] L2 is selected from the following amino acid residues or oligopeptide residues consisting of 2 to 5 amino acids, wherein the amino acids are selected from phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, and wherein the amino acid is optionally substituted by 1, 2, 3, or 4 R4 residues, and one of the amino acids is substituted by 1 R4 residue. H replace;

[0329] Preferably, L2 is selected from dipeptide, tripeptide, or tetrapeptide (preferably dipeptide or tripeptide) residues composed of the following amino acids, wherein the amino acids are selected from phenylalanine, isoleucine, leucine, valine, alanine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, citrulline, aspartic acid, and glycine, and wherein the amino acids are optionally substituted by 1, 2, 3, or 4 R4 residues, and one of the amino acids is substituted by 1 R4 residue. H replace;

[0330] Preferably, L2 is selected from valine-glutamic acid, valine-glutamine, valine-aspartic acid, valine-asparagine, glutamic acid-valine-alanine, glutamine-valine-alanine, aspartic acid-valine-alanine, and asparagine-valine-alanine, optionally substituted with 1, 2, 3, or 4 R4, and one of the amino acids is replaced by 1 R4. H replace;

[0331] Preferably, R H The substituted amino acids are selected from glutamic acid, glutamine, aspartic acid and asparagine, with glutamic acid and glutamine being preferred, and glutamic acid being even more preferred;

[0332] Preferably,

[0333] L2 is either -P1-AA1- or -AA2-P1-; where AA1 is connected to L3 and AA2 is connected to W2;

[0334] P1 is independently selected from glutamic acid, glutamine, aspartic acid, and asparagine, and is determined by one R H replace;

[0335] AA1 is selected from the following amino acid residues or oligopeptide residues consisting of 2-3 (preferably 2) or fewer amino acids; wherein the amino acid is selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably valine, alanine, leucine, and isoleucine, preferably valine and alanine, and preferably valine-alanine; and wherein the amino acid is optionally substituted by 1, 2, 3, 4, 5, or 6 (preferably 1, 2, 3, or 4) R4 residues;

[0336] AA2 is selected from the following amino acid residues or oligopeptide residues consisting of 2-3 or fewer amino acids; wherein the amino acid is selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably the following amino acid residues: valine, alanine, leucine, and isoleucine, with valine being the most preferred; and the amino acid is optionally substituted by 1, 2, 3, 4, 5, or 6 (preferably 1, 2, 3, or 4) R4 residues.

[0337] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein...

[0338] R H It is -H1-H2-NR2R3;

[0339] Wherein, H1 is selected from chemical bonds, -O-, -S-, -NR1-, -C(O)-, -S(O)- and -S(O)2-; preferably chemical bonds, -O-, -S- and -NR1-; preferably chemical bonds, -O- and -NR1-; preferably chemical bonds and -NR1-; preferably -NR1-;

[0340] H2 is -(CH2) a - wherein one, two or three methylene units are optionally and independently replaced by -O-, -S- or -NR1- (preferably -O-);

[0341] a = 1, 2, 3, 4, 5 or 6, preferably a = 1, 2, 3 or 4, preferably a = 1 or 2, preferably a = 2;

[0342] R1 is independently selected from H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups, preferably H or C 1-4 Alkyl or C 1-4 Haloalkyl, preferably H;

[0343] R2 and R3 are each independently selected from H and C. 1-6 Alkyl, C 1-6 The alkyl halogroup and the hydrophilic group of polyhydroxy alcohol, preferably H and the hydrophilic group of polyhydroxy alcohol, and at least one of R2 and R3 is a hydrophilic group of polyhydroxy alcohol;

[0344] Preferably,

[0345] The hydrophilic group of the polyhydroxy alcohol has the following structure: -X1(CR7OH)zX2R8;

[0346] Among them, X1 and X2 are independently selected from chemical bonds, C 1-6 Alkylene, -NR1-, -C(O)-, -S(O)- and -S(O)2-, preferably chemical bonds, C 1-6 Alkylene (preferably C) 1-4 Alkylene, preferably C 1-2 -alkylene), -NR1- and -C(O)-, preferably C 1-4 Alkylene, preferably C 1-2 Alkyl groups, such as methylene groups;

[0347] R7 is independently selected from H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups; preferably H or C 1-4 Alkyl or C 1-4 Halogenated alkyl; preferably H;

[0348] R8 is independently selected from H, CN, and -OR. a -NR b R c C 1-6 Alkyl or C 1-6 Halogenated alkyl groups, preferably H or -OR a C 1-6 Alkyl or C 1-6 Halogenated alkyl groups, preferably -OR a Preferred -OH;

[0349] z is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 3, 4, 5 or 6;

[0350] Preferably,

[0351] The polyhydroxy alcohol hydrophilic group is selected from... (Preferred) )and (Preferred) ).

[0352] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein...

[0353] R4 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl, C 1-6 Halogenated alkyl groups, polyethylene glycol, polysarcosine, pentose sugars, hexose sugars, sulfonic acid groups, methanesulfonyl groups, phosphoric acid groups, phosphite groups, quaternary ammonium salts, or groups selected from the following:

[0354] Preferably, R4 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl and C 1- 6-Hydroalkyl group.

[0355] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein...

[0356] L3 is selected from chemical bonds or the following structures: Preferred chemical bonds or Preferred chemical bonds or

[0357] Preferably, R5 is independently selected from H, D, halogen, C. 1-6 Alkyl and C 1-6 Halogenated alkyl groups;

[0358] Preferably,

[0359] R6 is selected from H, H is preferred.

[0360] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic compound or tautomer, or a pharmaceutically acceptable salt thereof, wherein D is selected from cytotoxins, antitumor drugs, anti-infective drugs or immunomodulatory drugs.

[0361] Preferably, D is a cytotoxic agent, such as a tubulin inhibitor, topoisomerase inhibitor, DNA alkylating agent, DNA chimera, enzyme inhibitor, immunomodulator, PROTAC, antimetabolite, bioactive peptide, or bioactive nucleotide sequence.

[0362] Preferably, D is selected from microtubule inhibitors, DNA topoisomerase inhibitors, drugs that interfere with DNA synthesis, DNA alkylating agents, DNA chimeras, enzyme inhibitors, RNA inhibitors, Bcl-xL inhibitors, NAMPT inhibitors, proteasome inhibitors, carbamycin, immunomodulators, PROTAC, antimetabolites, bioactive peptides, nucleotides, tumor signaling pathway inhibitors, histone deacetylase inhibitors, tumor angiogenesis inhibitors, cyclin inhibitors, drugs that act on structural proteins, metal complexes, or glycopeptide antibiotics.

[0363] Preferably, D is a cytotoxic substance, preferably selected from maytansine and its derivatives, olistatin and its derivatives, tubulysins and its derivatives, tubulin and its derivatives, cryptophytin and its derivatives, eribulin and its derivatives, pyrrolobenzodiazepines (PBDs) and their derivatives, enediyne molecules and their derivatives, pyroxine and its derivatives, and other active substances that inhibit tumor cell growth and promote tumor cell apoptosis or necrosis.

[0364] Preferably, D is selected from olistatin and its derivatives, camptothecin and its derivatives, maytansine and its derivatives, calcimycin and its derivatives, paclitaxel and its derivatives, pyrrolobenzodiazepines and their derivatives, pyroxine, doxorubicin, melphalan, mitomycin C, chlorambucil, and other active substances that inhibit tumor cell growth and promote tumor cell apoptosis or necrosis.

[0365] Preferably, D is selected from monomethylorlistatine E (MMAE), monomethylorlistatine F (MMAF), DM1, DM4, Dxd (CAS: 1599440-33-1), ixotecan (Dx-8951f), oxaliplatin, bleomycin, bleomycin, camptothecin, hydroxycamptothecin, 9-aminocamptothecin, SN-38, irinotecan, topotecan, belotetan, rubotecan, and actinomycin. D. Doxorubicin, Docalimicin, Daunorubicin, Mitoxantrone, Podophyllotoxin, Etoposide, Methotrexate, 5-Fluorouracil, Cytarabine, Gemcitabine, Mercaptopurine, Pentostatin, Fludarabine, Clardribine, Nerapine, Vincristine, Vincristine, Paclitaxel, Docetaxel, Cabazitaxel, Serine / Threonine kinase inhibitors, Tyrosine kinase inhibitors, Aspartate kinase inhibitors, or Histidine kinase inhibitors;

[0366] Preferably, D is selected from microtubule inhibitors, topoisomerase I inhibitors, and DNA alkylating agents, such as MMAE, MMAF, Dxd, or Dx-8951f, with MMAE or Dx-8951f being more preferred.

[0367] In a more specific embodiment, the present invention provides a compound of formula (I) above, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, having the following general formula:

[0368] in,

[0369] b = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably b = 0, 1, 2, 3, 4, 5 or 6, preferably b = 0, 1, 2 or 3, preferably b = 2;

[0370] The remaining variables are as defined in this invention.

[0371] In a more specific embodiment, the present invention provides the above-mentioned compound, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, having the structure of formula (I-1):

[0372] in,

[0373] *1 is a chiral center, independently selected from the (S) or (R) configuration, or a racemic form; the (S) configuration is preferred;

[0374] U is selected from

[0375] W1 is -W 1a -W 1b -;

[0376] W 1a Selected from chemical bonds or -(CH2) m24 -; Preferred chemical bonds;

[0377] W 1b Selected from -C(O)O- or -C(O)NH-; preferably -C(O)NH-;

[0378] m24 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; preferably 1, 2, 3, 4, 5 or 6;

[0379] L1 is selected from -(CH2CH2O) n11 -(CH2) m11 -or-(CH2) m21 -;

[0380] Where n11 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0381] m11 = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0382] m21 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0383] W2 is -C(O)-;

[0384] a = 1, 2, 3, 4, 5 or 6, preferably a = 1, 2, 3 or 4, preferably a = 1 or 2, preferably a = 2;

[0385] b = 0, 1, 2, 3, 4, 5 or 6, preferably b = 0, 1, 2 or 3, preferably b = 2;

[0386] R2 and R3 are each independently selected from H and C. 1-6 Alkyl, C 1-6 The alkyl halogroup and the hydrophilic group of polyhydroxy alcohol, preferably H and the hydrophilic group of polyhydroxy alcohol, and at least one of R2 and R3 is a hydrophilic group of polyhydroxy alcohol;

[0387] The polyhydroxy alcohol hydrophilic group is selected from... (Preferred) )and (Preferred) );

[0388] AA1 is selected from the following amino acid residues or oligopeptide residues consisting of 2-3 (preferably 2) or fewer amino acids; wherein the amino acid is selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably valine, alanine, leucine, and isoleucine, preferably valine and alanine, and preferably valine-alanine; and wherein the amino acid is optionally substituted by 1, 2, 3, 4, 5, or 6 R4 residues;

[0389] The N-terminus of the amino acid residue or oligopeptide residue is linked to -C(O)-, and the C-terminus is linked to L3;

[0390] R4 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl and C 1-6 Halogenated alkyl groups;

[0391] L3 is a chemical bond or Preferred chemical bonds or

[0392] NH is connected to L2, and C(O) is connected to D;

[0393] R5 is independently selected from H, D, halogen, and C. 1-6 Alkyl and C 1-6 Halogenated alkyl groups;

[0394] t = 0, 1, 2, 3 or 4;

[0395] D is selected from microtubule inhibitors, topoisomerase I inhibitors, and DNA alkylating agents, such as MMAE, MMAF, Dxd, or Dx-8951f, preferably MMAE or Dx-8951f.

[0396] In a more specific embodiment, the present invention provides the above-mentioned compound, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, having the structure of formula (I-2):

[0397] in,

[0398] *2 is a chiral center, independently selected from the (S) or (R) configuration, or a racemic form; the (S) configuration is preferred;

[0399] U is selected from

[0400] W1 is -W 1a -W 1b -;

[0401] W 1a Selected from chemical bonds or -(CH2) m24 -; Preferred chemical bonds;

[0402] W 1b Selected from -C(O)O- or -C(O)NH-; preferably -C(O)NH-;

[0403] m24 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; preferably 1, 2, 3, 4, 5 or 6;

[0404] L1 is selected from -(CH2CH2O) n11 -(CH2) m11 -or-(CH2) m21 -;

[0405] Where n11 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0406] m11 = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0407] m21 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0408] W2 is -C(O)-;

[0409] AA2 is selected from the following amino acid residues or oligopeptide residues consisting of 2-3 or fewer amino acids; wherein the amino acids are selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably the following amino acid residues: valine, alanine, leucine, and isoleucine, with valine being the most preferred; and wherein the amino acids are optionally substituted by 1, 2, 3, 4, 5, or 6 R4 residues;

[0410] The N-terminus of the amino acid residue or oligopeptide residue is linked to W2, and the C-terminus is linked to -NH-.

[0411] R4 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl and C 1-6 Halogenated alkyl groups;

[0412] a = 1, 2, 3, 4, 5 or 6, preferably a = 1, 2, 3 or 4, preferably a = 1 or 2, preferably a = 2;

[0413] b = 0, 1, 2, 3, 4, 5 or 6, preferably b = 0, 1, 2 or 3, preferably b = 2;

[0414] R2 and R3 are each independently selected from H and C. 1-6 Alkyl, C 1-6 The alkyl halogroup and the hydrophilic group of polyhydroxy alcohol, preferably H and the hydrophilic group of polyhydroxy alcohol, and at least one of R2 and R3 is a hydrophilic group of polyhydroxy alcohol;

[0415] The polyhydroxy alcohol hydrophilic group is selected from... (Preferred) )and (Preferred) );

[0416] L3 is a chemical bond or Preferred chemical bonds or Preferred chemical bonds;

[0417] NH is connected to L2, and C(O) is connected to D;

[0418] R5 is independently selected from H, D, halogen, and C. 1-6 Alkyl and C 1-6 Halogenated alkyl groups;

[0419] t = 0, 1, 2, 3 or 4;

[0420] D is selected from microtubule inhibitors, topoisomerase I inhibitors, and DNA alkylating agents, such as MMAE, MMAF, Dxd, or Dx-8951f, preferably MMAE or Dx-8951f.

[0421] In a more specific embodiment, the present invention provides the above-described compound, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from:

[0422] In a more specific embodiment, the present invention also provides a compound of formula (II), or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof:

[0423] in,

[0424] A is a targeted molecule;

[0425] U' is a group formed after the reaction of the linker and the thiol group;

[0426] x = 1, 2, 3, 4, 5, 6, 7 or 8;

[0427] The remaining variables are as defined in this invention.

[0428] In a more specific embodiment, the present invention provides the above-mentioned compound, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic compound, or tautomer, or a pharmaceutically acceptable salt thereof, wherein A is selected from proteins, antibodies, nanobodies, bispecific antibodies, antibody fragments, fusion proteins, peptides, enzymes, and small molecules; A is preferably an antibody, preferably a monoclonal antibody, such as a monospecific monoclonal antibody and a bispecific monoclonal antibody; A is preferably an IgG antibody targeting tumor-associated antigens.

[0429] In a more specific embodiment, the present invention provides the above-mentioned compound, or its prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein A is an antibody, and the tumor-associated antigens targeted by the antibody include, but are not limited to: HER2, Trop-2, Claudin-6, Claudin-9, Claudin-18.2, EGFR, c-Met, CD19, PSMA, Muc1, BCMA, PD-L1, CD33, CD30, CD22, CD79b, Nectin-4, CD19, tissue factor, FRα, B7-H3, B7-H4, CDH3, CDH6, CD H17, CD56, CD37, HER3, ROR1, MSLN, TNF-α, CD25, ENPP3, Muc1, Axl, CD20, ROR2, GPNMB, CEACAM5, CEACAM6, EPHA5, TL1A, CD138, GC-C, LIV-1, CA6, FUT3, IGF -1R, CTLA4, RNF43, DPEP3, 5T4, ITGB6, EFNA4, CD228, Notch3, CD46, CAIX, SLAMF6, ADAM9, GD3, TDGF1, SLAMF2, CLL-1, CD123, FCRL5, TIM1, sTn, ETB, Globo H, CD38, Ly6E, SLITRK6, GPR20, FGFR2, FGFR2b, Muc16, CD5 1. SLAMF7, LAMP-1, CD74, CCR7, PTK7, SEZ6, LYFD3, TAA, PRL receptor, FGFR3, KAAG1, STEAP1, Flt3, Muc1, LRRC15, CD44, CD70, EphA2, CXCR4, DDR1, DKL1, FOLR, CD45, DSG2, ALK, TRAIL, EpCAM, VEGFR2, CD47, CD49, SS EA-4, DCLK1, OacGD2, CD73, EN01, BSG, CD24, GLUT1 and GPRC5D, preferably HER2, HER3, EGFR, Trop-2, Claudin-6, Claudin-18.2, B7-H3, B7-H4, CDH3, CDH6, CDH17, FRα, ROR1, ALPP, CEACAM5, CEACAM6, EPHA5, TL1A or FOLR.

[0430] In a more specific embodiment, the present invention provides the above-described compound, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein U' is selected from: Preferred Preferred The carbon atom at the # end is linked to the sulfur atom in the cysteine ​​residue of the targeted molecule A through a thioether bond.

[0431] In a more specific embodiment, the present invention provides the above-mentioned compound, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic compound, or tautomer, or a pharmaceutically acceptable salt thereof, wherein x = 2, 3, 4, 5, 6, 7, or 8, preferably x = 2, 4, 6, or 8, more preferably x = 4, 6, or 8, and even more preferably x = 4 or 8.

[0432] In a more specific embodiment, the present invention provides the above-described compound, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, having the following general formula:

[0433] The variables are as defined in this invention.

[0434] In a more specific embodiment, the present invention provides the above-described compound, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

[0435] in,

[0436] The antibody is indicated; preferably a monoclonal antibody or a bispecific antibody; preferably an IgG1 type monoclonal antibody; more preferably an IgG1 type monoclonal antibody against HER2 and CDH76.

[0437] Treatment

[0438] The targeting molecules described in this application may be protein hormones, lectins, growth factors, antibodies, or other molecules that can bind to cells, receptors, and / or antigens. For example, the targeting molecules in this application may be anti-HER2 antibodies, anti-B7-H3 antibodies, including IgG type antibodies and HCAb type antibodies, or their antigen-binding fragments.

[0439] Because the antibody-drug conjugate provided in this application can target specific cell populations and bind to cell surface-specific proteins (antigens), the drug is released into the cells in its active form via conjugate endocytosis or drug infiltration. Therefore, the antibody-drug conjugate of this application can be used to treat diseases. The antibody-drug conjugate of this application can be administered to subjects (e.g., humans) in therapeutically effective amounts via appropriate routes. Subjects requiring treatment may be patients at risk or suspected of having a condition related to the activity or expression level of a specific antigen. Such patients can be identified through routine physical examinations.

[0440] When treated with the antibody-drug conjugate of this application, delivery can be performed using methods conventional in the art. For example, it can be introduced into cells using liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, or bioadhesive microspheres. Alternatively, the nucleic acid or carrier can be delivered locally by direct injection or by using an infusion pump. Other methods may include the use of various transport and carrier systems using conjugates and biodegradable polymers.

[0441] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to: the activity of the specific compound used, the patient's age, the patient's weight, the patient's health status, the patient's behavior, the patient's diet, the timing of administration, the route of administration, the rate of excretion, and the combination of drugs; in addition, the optimal mode of treatment, such as the treatment regimen, the daily dosage of the compound described in this application or its pharmaceutically acceptable salts, prodrugs, hydrates, solvates, enantiomers, diastereomers, mesosomes, racemates, racemates, or tautomers, or mixtures thereof, or the type of pharmaceutically acceptable salt, can be verified based on conventional treatment regimens.

[0442] The compounds of this application can be administered alone or in combination with other pharmaceutically acceptable therapeutic agents. When using the pharmaceutical composition, a safe and effective amount of the compounds of this application may be applied to a mammal (such as a human) requiring treatment, wherein the dose administered may be a pharmaceutically considered effective dose, and the specific dose may also take into account factors such as the route of administration and the patient's health condition.

[0443] This application provides the use of a compound of this application, or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer thereof, or a pharmaceutical composition of this application, in the preparation of a medicament for treating and / or preventing tumors. For example, the tumor may be selected from tumors associated with the expression of targets such as HER2 and B7-H3. For example, tumors associated with the expression of targets such as HER2 and B7-H3 include tumors with high expression of the targets and / or tumors positive for the targets. For example, the tumor includes solid tumors and / or hematologic malignancies. For example, the tumor includes breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, colorectal cancer, gastric cancer, glioma, or mesothelioma.

[0444] This application provides a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer thereof, or a pharmaceutical composition comprising the present application, which can be used to treat and / or prevent tumors. For example, the tumor may be selected from tumors associated with the expression of targets such as HER2, B7-H3, etc. For example, the tumor associated with the expression of the target includes tumors with high expression of the target and / or tumors positive for the target. For example, the tumor includes solid tumors and / or hematologic malignancies. For example, the tumor is selected from the group consisting of breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, colorectal cancer, gastric cancer, glioma, and mesothelioma.

[0445] This application provides a method for preventing and / or treating tumors, which may include administering to a subject a compound of this application, or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic compound, or tautomer, or a pharmaceutical composition of this application. For example, the tumor may be selected from tumors associated with the expression of targets such as HER2, B7-H3, etc. For example, the tumor associated with the expression of the target includes tumors with high expression of the target and / or tumors positive for the target. For example, the tumor includes solid tumors and / or hematologic malignancies. For example, the tumor is selected from the group consisting of breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, colorectal cancer, gastric cancer, glioma, and mesothelioma.

[0446] Pharmaceutical Composition

[0447] In addition to the active compound, the pharmaceutical composition described in this application may contain one or more excipients, which may be selected from the group consisting of fillers (diluents), binders, wetting agents, disintegrants, and excipients. Depending on the method of administration, the composition may contain 0.1 to 99% by weight of the active compound.

[0448] Pharmaceutical compositions containing active ingredients may be in oral forms, such as tablets, lozenges, tablets, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups. Oral compositions may be prepared according to any method known in the art for preparing pharmaceutical compositions, and may contain binders, fillers, lubricants, disintegrants, or pharmaceutically acceptable wetting agents, and may also contain one or more ingredients selected from the group consisting of sweeteners, flavoring agents, coloring agents, and preservatives.

[0449] Aqueous suspensions may contain active substances and excipients suitable for mixing. Aqueous suspensions may also contain one or more preservatives, such as one or more colorants, one or more flavoring agents, and one or more sweeteners. Oil suspensions can be prepared by suspending the active ingredient in vegetable oil. Oil suspensions may contain thickeners. The aforementioned sweeteners and flavoring agents may also be added.

[0450] The pharmaceutical composition may also provide the active ingredient as a dispersible powder or granules for preparing an aqueous suspension, by adding one or more of a water-mixing dispersant, wetting agent, suspending agent, or preservative. Other excipients such as sweeteners, flavoring agents, and coloring agents may also be added. These compositions are preserved by adding antioxidants such as ascorbic acid. The pharmaceutical compositions of this application may also be in the form of an oil-in-water emulsion.

[0451] The pharmaceutical composition may be in the form of a sterile injectable aqueous solution. Acceptable solvents or media that can be used include water, Ringer's solution, and isotonic sodium chloride solution. The sterile injectable formulation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in the oil phase. For example, the active ingredient may be dissolved in a mixture of soybean oil and lecithin. The oil solution may then be treated with a mixture of water and glycerol to form a microemulsion. The injection solution or microemulsion may be injected into the patient's bloodstream via local large-volume injection. Alternatively, the solution and microemulsion may be administered in a manner that maintains a constant circulating concentration of the compound of this application. To maintain such a constant concentration, a continuous intravenous delivery device may be used. For example, the device may be an intravenous infusion pump.

[0452] The pharmaceutical composition may be in the form of a sterile injectable aqueous or oil suspension for intramuscular and subcutaneous administration. This suspension may be formulated using suitable dispersants or wetting agents and suspending agents described above, according to known techniques. The sterile injectable formulation may also be a sterile injectable solution or suspension prepared in a parenteral-acceptable, non-toxic diluent or solvent. Alternatively, a sterile fixative oil may be conveniently used as a solvent or suspension medium.

[0453] The compounds of this application may be administered in suppository form for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable, non-irritating excipient that is solid at normal temperatures but liquid in the rectum, and thus dissolves in the rectum to release the drug. Such substances include cocoa butter, glycerin gelatin, hydrogenated vegetable oils, polyethylene glycol of various molecular weights, and mixtures of fatty acid esters of polyethylene glycol.

[0454] The pharmaceutical composition of this application may contain a safe and effective amount of the antibody-drug conjugate of this application and a pharmaceutically acceptable carrier. Such carriers may include (but are not limited to) saline, buffer solutions, glucose, water, glycerol, ethanol, and combinations thereof. Generally, the pharmaceutical formulation should be matched to the route of administration. The pharmaceutical composition of this application may be formulated as a solution, for example, prepared using conventional methods with physiological saline or an aqueous solution containing glucose and other excipients. The pharmaceutical composition may be manufactured under aseptic conditions. The dosage of the active ingredient may be a therapeutically effective amount.

[0455] The effective amount of the antibody-drug conjugate described in this application can vary depending on the administration method and the severity of the disease to be treated. The selection of the effective amount can be determined by those skilled in the art based on various factors (e.g., through clinical trials). These factors may include, but are not limited to: the pharmacokinetic parameters of the bifunctional antibody-drug conjugate, such as bioavailability, metabolism, and half-life; the severity of the disease to be treated, the patient's weight, the patient's immune status, and the route of administration. Generally, satisfactory results can be obtained when the antibody-drug conjugate of this application is administered daily at an appropriate dose. For example, due to the urgency of the treatment condition, several separate doses can be administered daily, or the dose can be reduced proportionally.

[0456] Example

[0457] The following specific embodiments illustrate the detailed implementation of this application. Those skilled in the art can easily understand other advantages and effects of this invention from the content disclosed in this specification. It is not intended to limit one to any theory; the embodiments described below are merely for illustrating the compounds, preparation methods, and uses of this application, and are not intended to limit the scope of this invention.

[0458] The abbreviations used in this article are defined as follows: ADC (antibody-drug conjugate): antibody-drug conjugate; Ala (Alanine): alanine; Boc (t-Butyloxycarbonyl): t-Butyloxycarbonyl; Cit (Citrulline): citrulline; DAR (Drug to antibody ratio): antibody-drug molar ratio; DCM (Dichloromethane): dichloromethane; DIPEA (N,N-Diisopropylethylamine): N,N-Diisopropylethylamine; DMAC (Dimethylacetamide): N,N-Dimethylacetamide; DMF (N,N-Dimethylformamide): N,N-Dimethylformamide; DMSO (Dimethyl Sulphoxide): dimethyl sulfoxide; DX-8951f (Exatecan Mesylate): exatecan mesylate; EA (ethyl acetate): ethyl acetate; EEDQ (N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline): N-ethoxyacyl-2-ethoxy-1,2-dihydroquinoline; Fmoc (Fluorenylmethyloxycarbonyl): Fluorenylmethyloxycarbonyl; HATU: N,N,N′,N′-Tetramethyl-O-(7-azabenzotriazol-1-yl)hexafluorophosphate urea; HER2 (Human epidermal growth factor receptor 2): Human epidermal growth factor receptor 2; HIC (Hydrophobic Interaction Chromatography): Hydrophobic interaction chromatography; His (Histidine): Histidine; HOBt (N-Hydroxybenzotrizole): 1-Hydroxybenzotriazole; m-CPBA (m-Chloroperbenzoic Acid): m-Chloroperbenzoic acid; mM (Millimoles): Millimoles; Me (methyl): Methyl MMAE (Monomethyl auristatin) E): Monomethyl auristatin E; MMAF (Monomethyl auristatin F): Monomethyl auristatin F; NHS (N-Hydroxysuccinimide): N-hydroxysuccinimide; NAC (N-Acetyl-L-cysteine): N-acetyl-L-cysteine;NPC (Bis(4-nitrophenyl)carbonate): Bis(p-nitrophenyl)carbonate; PAB (p-Aminobenzyl alcohol): p-aminobenzyl alcohol; Su / SuOH (Succinimide): Succinimide; TCEP (Tris(2-carboxyethyl)phosphine): Tris(2-carboxyethyl)phosphine; TFA (Trifluoroacetic acid): Trifluoroacetic acid; THF (Tetrahydrofuran): Tetrahydrofuran; VA (Valine-Alanine, Val-Ala): Valine-alanine dipeptide; Val (Valine): Valine; VC (Valine-Citrulline, Val-Cit): Valine-citrulline dipeptide; EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; TEA: Triethylamine.

[0459] Unless otherwise specified in the examples, the procedures should be performed under standard conditions or conditions recommended by the manufacturer. Reagents or instruments whose manufacturers are not specified are all commercially available products.

[0460] Example 1: Preparation of Compound-1

[0461] The specific synthesis steps are as follows.

[0462] Step 1-1: Preparation of M1

[0463] Methyl 6-chloro-5-nitropyridinecarboxylate (100 g, 0.463 mol) and NH4Cl (123 g, 2.315 mol) were dissolved in 1500 mL of an ethanol / water mixture (EtOH / H2O volume ratio 5:1). Iron powder (129.6 g, 2.315 mol) was added to the reaction mixture under stirring. The mixture was stirred at 60 °C for 16 hours under nitrogen protection. After the reaction was complete, the reaction mixture was filtered, and the filtrate was extracted with DCM (1000 mL × 3 times). The combined organic layers were washed with saturated brine, dried over Na2SO4, and concentrated to obtain crude intermediate M1 as a yellow solid powder, weighing approximately 70 g, with a yield of approximately 81%. The crude product contained a small amount (~5%) of the ethyl ester byproduct M1'. It was used directly in the next reaction without further purification. M1: MS (ESI) m / z: 187.2 [M+H] + M1':MS(ESI)m / z:201.1[M+H] + .

[0464] Steps 1-2: Preparation of M2

[0465] Crude M1 (70 g, 0.375 mol) was dissolved in 2 L of DMF. While stirring, potassium ethyl xanthate (120.26 g, 0.750 mol) was added to the reaction mixture. After addition, the mixture was stirred at 100 °C for 48 hours. After the reaction was complete, the mixture was poured into 5 L of water, and the pH was adjusted to 3–4 with 1 N HCl. The mixture was filtered, and the filter cake was dried to obtain crude intermediate M2 as a yellow solid powder, weighing approximately 40 g, with a yield of approximately 47%. The crude product contained a small amount (5%–10%) of the ethyl ester byproduct M2'. It was used directly in the next reaction without further purification. M2: MS (ESI) m / z: 226.9 [M+H] + M2':MS(ESI)m / z:240.9[M+H] + .

[0466] Steps 1-3: Preparation of M3

[0467] Crude M2 ​​(40 g, 0.176 mol) was dissolved in 400 mL of THF. After the solid was completely dissolved, the mixture was cooled to approximately 0 °C in an ice bath. While stirring, triethylamine (TEA, 35.55 g, 0.352 mol) and methyl iodide (MeI, 37.49 g, 0.264 mol) were added to the reaction mixture. After the addition was complete, the mixture was stirred for 2 hours under nitrogen protection. The mixture was then poured into water and extracted with EA (500 mL * 3). The organic layer was washed with brine, dried with Na2SO4, and concentrated to obtain crude intermediate M3 as a yellow solid powder, weighing approximately 40 g, with a yield of approximately 95%. The crude product contained a small amount (5%–10%) of the ethyl ester byproduct M3'. This byproduct was used directly in the next reaction without further purification. M3: MS (ESI) m / z: 241.3 [M+H] + M3':MS(ESI)m / z:255.3[M+H] + .

[0468] Steps 1-4: Preparation of M4

[0469] Crude M3 (40 g, 0.166 mol) was dissolved in a THF / H2O mixture of 3:1 (800 mL). After the solid was completely dissolved, lithium hydroxide monohydrate (13.97 g, 0.333 mol) was added to the reaction solution. The mixture was stirred at room temperature for 2 hours. After the reaction was complete, the mixture was concentrated, diluted with water, and the pH was adjusted to 3-4 with 1 N HCl. The mixture was filtered, and the filter cake was dried to obtain intermediate M4 as a yellow solid powder, with a mass of approximately 30 g and a yield of approximately 80%. It was used directly in the next reaction without further purification. 1H-NMR(400MHz, DMSO_d6)δ8.21(d,J=8.4Hz,1H),8.08(d,J=8.4Hz,1H),2.80(s,3H).MS(ESI)m / z:227.3[M+H] + .

[0470] Steps 1-5: Preparation of M5

[0471] Compound M4 (10.0 g, 44.19 mmol) was dissolved in DMF (150 mL), and N-hydroxysuccinimide (NHS, 7.6 g, 66.29 mmol) and EDCI (16.9 g, 88.38 mmol) were added to the mixture. The mixture was reacted at room temperature for 16 hours. After the reaction was complete, the mixture was slowly poured into ice water (750 mL), and a solid precipitated. The solid was filtered, and the filter cake was washed with water (100 mL). After drying, the active ester intermediate was obtained as a pale yellow solid powder with a mass of approximately 13.4 g. This powder was used directly in the next reaction without being allowed to stand for a long time.

[0472] The above-mentioned active ester intermediate was redissolved in DMF (150 mL), followed by the sequential addition of 6-aminohexanoic acid (5.3 g, 40.22 mmol) and DIPEA (5.2 g, 40.22 mmol). The reaction was carried out at room temperature for 16 hours. After the reaction was complete, the mixture was slowly poured into ice water (1000 mL), and the pH was adjusted to 5-6 with 1 M hydrochloric acid solution. A solid precipitated, which was filtered, and the filter cake was washed with water (200 mL). After drying, compound M5 was obtained as an off-white solid powder, 11.6 g, with a two-step yield of approximately 77%. MS (EI) m / z: 339.92 [M+H] + .

[0473] Steps 1-6: Preparation of M6

[0474] To a mixture of compound M5 (11.0 g, 32.41 mmol) and DCM (300 mL), m-CPBA (85% purity, 26.3 g, 129.64 mmol) was added. The reaction was carried out at room temperature for 16 hours, monitored by LC-MS. After the reaction was complete, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by rapid silica gel column chromatography (eluent MeOH / DCM, gradient 0% to 10%) to give compound M6 as a white solid powder, 8.7 g, yield approximately 73%. MS (EI) m / z: 372.04 [M+H] + .

[0475] Steps 1-7: Preparation of M7

[0476] Compound M6 (7.4 g, 19.92 mmol) was dissolved in DMF (74 mL), followed by the sequential addition of N-hydroxysuccinimide (4.6 g, 39.84 mmol) and EDCI (7.6 g, 39.84 mmol). The reaction was carried out at room temperature for 8 hours, and the reaction was monitored by LC-MS. After the reaction was complete, the mixture was slowly poured into 400 mL of ice water, and the aqueous phase was extracted with ethyl acetate (400 mL × 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by rapid silica gel column chromatography (eluent MeOH / DCM, gradient 0% to 10%) to give compound M7 as a white solid powder, 4.9 g, with a yield of approximately 53%. MS (EI) m / z: 469.20 [M+H] + .

[0477] Steps 1-8: Preparation of M8

[0478] Fluorenemethyloxycarbonyl-L-glutamic acid-1-tert-butyl ester (5 g, 11.75 mmol) was dissolved in DMF (50 mL), and EDCI (9.0 g, 47 mmol), HOBt (1.9 g, 14.1 mmol), and mono-Boc ethylenediamine (2.07 g, 12.93 mmol) were added sequentially with stirring. The reaction was stirred at room temperature for 4 hours, and LC-MS monitoring showed the reaction was complete. The reaction solution was poured into water (300 mL), and a precipitate formed. The insoluble matter was filtered off, the filter cake was washed with water (100 mL), and dried to obtain compound M8 as an off-white solid powder, 6.2 g, with a yield of approximately 93%. MS (EI) m / z: 568.36 [M+H] + 590.37 [M+Na] + .

[0479] Steps 1-9: Preparation of M9

[0480] M8 (1.0 g, 1.76 mmol) was dispersed in DCM (20 mL), and after the addition of trifluoroacetic acid (TFA, 3 mL), the solid completely dissolved. The mixture was stirred overnight at room temperature. After the reaction was complete, the solution was concentrated under reduced pressure to remove the dissolved residue, resulting in an orange oily substance. The oily substance was dispersed in methyl tert-butyl ether (15 mL), and a large amount of insoluble matter precipitated out. The mixture was filtered, and the filter cake was washed with methyl tert-butyl ether and thoroughly dried to give M9 as an off-white solid, 807 mg, with a yield of approximately 90%. It was used directly in the next reaction without further purification. MS (EI) m / z: 411.97 [M+H] + .

[0481] Steps 1-10: Preparation of M10

[0482] The crude M9 (<1.76 mmol) described in steps 1-9 was redissolved in MeOH (20 mL). While stirring, glucose (635 mg, 3.52 mmol) and a catalytic amount of glacial acetic acid were added to the mixture. After heating to 60 °C for 2 hours, the reaction was stopped and allowed to return to room temperature. Sodium cyanoborohydride (221 mg, 3.52 mmol) was then added while stirring. This process of adding glucose and sodium cyanoborohydride was repeated 2-3 times until the starting material M9 and the monosubstituted intermediate were completely consumed. After the reaction was complete, heating was stopped and the reaction mixture was allowed to return to room temperature. Insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure to obtain crude M10 as a white, bubbly solid. Further purification by C18 reverse-phase chromatography and lyophilization yielded compound M10 as a white solid powder, 914 mg, with a yield of approximately 78%. MS (EI) m / z: 740.35 [M+H] + .

[0483] Steps 1-11: Preparation of M11

[0484] Fmoc-Ala-NHS (10 g, 22.9 mM) was dissolved in a DME / THF mixed solution (2:1, 100 mL). After complete dissolution, a NaHCO3 solution of alanine (Ala; 2.65 g, 29.77 mM) was added, and the mixture was stirred at room temperature for 20 hours. After the reaction was complete, the reaction solution was poured into a 15% citric acid aqueous solution while stirring, resulting in the precipitation of a jelly-like insoluble substance. The mixture was filtered, and the filter cake was thoroughly dried under vacuum. After further drying, the product was slurried twice with diethyl ether to obtain product M11 as a white solid powder, 8.27 g, with a yield of approximately 88%. 1 H NMR (400MHz, DMSO-) d6 ): δ0.88(dd,6H),1.27(d,3H),1.96(m,1H),3.89(q,1H),4.22(m,4H),7.33(t,2H),7.43(m,3H),7.74(t 2H),7.89(d,2H),8.25(d,1H),12.48(s,1H).MS(EI)m / z:411.23[M+H]+.

[0485] Steps 1-12: Preparation of M12

[0486] Compound M11 (5 g, 12.2 mM) was dissolved in a DCM / MeOH mixed solution (2:1, 90 mL). After complete dissolution, p-aminobenzyl alcohol (PAB; 3.0 g, 24.4 mM) and EEDQ (6.0 g, 24.4 mM) were added. The reaction was stirred at room temperature in the dark for more than 36 hours. After the reaction was completed, the solvent was removed by concentration under reduced pressure. The residue was slurryed three times with diethyl ether to obtain product M12 as a white solid powder, 5.85 g, with a yield of approximately 93%.1 HNMR (400MHz, DMSO-d6): δ0.88(dd,6H),1.30(d,3H),2.00(m,1H),3.91(t,1H),4.22(q,2H),4.30(t,1H),4.40(br,1H),4.42(d,2H),5.13 (t,1H),7.24(t,2H),7.34(t,2H),7.41(t,2H),7.52(q,3H),7.75(t,2H),7.89(d,2H),8.22(d,1H),9.96(s,1H).MS(EI)m / z:516.29[M+H] + 538.20 [M+Na] + .

[0487] Steps 1-13: Preparation of M13

[0488] Compound M12 (5.0 g, 9.7 mmol) was dissolved in DMF (50 mL). After complete dissolution, p-nitrophenol carbonate (NPC; 5.9 g, 19.4 mmol) and DIPEA (1.88 g, 14.55 mM) were added. The mixture was stirred overnight at room temperature. After the reaction was complete, the solvent was removed by concentration under reduced pressure. The residue was slurryed three times with diethyl ether. Filtration yielded 6.0 g of product M13 as a white solid powder, with a yield of approximately 92%. The obtained material was directly used for the next reaction without further purification. MS (EI) m / z: 681.24 [M+H] + 703.20 [M+Na] + .

[0489] Steps 1-14: Preparation of M14

[0490] Compound M13 (114 mg, 0.167 mM) was dissolved in DMF (40 mL). After complete dissolution, MMAE (100 mg, 0.139 mM), HOBt (18.82 mg, 0.139 mM), and DIPEA (36 mg, 0.279 mM) were added. The reaction was stirred overnight at room temperature. After the reaction was complete, the solvent was removed by concentration under reduced pressure. The residue was slurried with diethyl ether. After filtration, approximately 181 mg of crude white solid powder, product M14, was obtained, with a yield of approximately 86%. MS (EI) m / z: 630.34 [M+2H] 2+ MS(ESI) m / z: 1259.7341 [M+H] + .

[0491] Steps 1-15: Preparation of M15

[0492] Compound M14 (126 mg, 0.1 mM) was dissolved in DMF (20 mL), and diethylamine (1 mL) was added. The mixture was stirred at room temperature for half an hour, and the starting material disappeared as detected by LC / MS. The solvent was removed by concentration under reduced pressure, and the residue was slurried with diethyl ether and filtered. The filter cake was further purified by C18 reversed-phase column chromatography to obtain product M15 as a white solid powder, 74 mg, with a yield of approximately 71%. The product is hygroscopic and was directly used in the next reaction without being left to stand. MS (EI) m / z: 1037.68 [M+H] + .

[0493] Steps 1-16: Preparation of M16

[0494] M16 (70 mg, 0.0675 mmol) and M10 (60 mg, 0.081 mmol) were dissolved in DMF (10 mL), and EDCI (38.8 mg, 0.20 mmol) and HOBt (18.24 mg, 0.135 mmol) were added to the reaction solution. The reaction mixture was stirred overnight under nitrogen protection. After the reaction was complete, the solvent was removed by concentration under reduced pressure. EA was added to the residue, the insoluble matter was dispersed by sonication, and the mixture was filtered to obtain crude M16. This crude product was used directly in the next step without further purification. MS (EI) m / z: 880.01 [M+2H] 2+ .

[0495] Steps 1-17: Preparation of M17

[0496] Following the synthetic method for M15, compound M17 was prepared by replacing M14 with M16 in piperidine dissolution to remove the Fmoc protecting group. The compound was a white solid powder with a yield of approximately 90%. MS (EI) m / z: 769.26 [M+2H] 2+ .

[0497] Steps 1-18: Preparation of target compound-1

[0498] M17 (50 mg, 0.0325 mmol) and M7 (30 mg, 0.065 mmol) were dissolved in DMF (10 mL), and a catalytic amount of DIPEA was added. The mixture was stirred overnight at room temperature. After the reaction was complete, the solvent was removed by concentration under reduced pressure. EA was added to the residue, and the insoluble matter was dispersed by sonication. The mixture was filtered to obtain crude compound-1. Further purification by C18 reversed-phase column chromatography yielded compound-1 as a white solid powder, 41 mg, with a yield of approximately 67%. MS (EI) m / z: 945.53 [M+2H] 2+ .

[0499] Example 2: Preparation of Compound-2

[0500] The specific synthesis steps are as follows.

[0501] Step 2-1: Preparation of M18

[0502] Following the synthetic method for compound M5, compound M18 was prepared by replacing 6-aminohexanoic acid with 1-amino-3,6,9,12-tetraoxopentadecane-15-acid. This yielded a pale yellow, waxy, viscous oil with approximately 70% yield. MS (ESI) m / z: 474.4 [M+H] + .

[0503] Step 2-2: Preparation of M19

[0504] M18 (30.0 g, 0.0634 mol) was dissolved in a mixed solution of EtOH / H2O (280 mL + 280 mL). After complete dissolution, hexaammonium molybdate (3.68 g, 3.17 mmol) and H2O2 (29.2 g, 0.317 mol) were added to the reaction solution. Under nitrogen protection, the reaction mixture was stirred at 40 °C for 16 hours. The mixture was concentrated to obtain a crude yellow oily product, which was further purified by column chromatography and concentrated to obtain M19 as a light yellow viscous oily product, 30 g, with a yield of approximately 94%. MS (ESI) m / z: 506.0 [M+H] + .

[0505] Steps 2-3: Preparation of M20

[0506] M19 (20.0 g, 0.0395 mol) was dissolved in DCM (200 mL). Under stirring at room temperature, once the oily substance was evenly dispersed, NHS (9.0 g, 0.079 mol) and EDCI (15.1 g, 0.0709 mol) were added sequentially. The reaction mixture was stirred at 25 °C for 12 hours under a nitrogen atmosphere. The mixture was concentrated to obtain a crude product. The crude product was purified by silica gel chromatography (PE / EA = 1 / 2) to obtain M20 as a yellow, viscous oily substance, 13.6 g, with a yield of approximately 94%. 1 H NMR (400MHz, CDCl3) δ8.59(d,J=8.6Hz,1H),8.51(d,J=8.6Hz,1H),8.29(s,1H),3.86-3.81(m,2H),3.74-3.71(m,4H),3.71-3 .69(m,4H),3.68-3.66(m,4H),3.65-3.63(m,4H),3.45(s,3H),2.90-2.87(m,2H),2.86-2.81(m,4H).MS(ESI)m / z:603.0[M+H] + .

[0507] Steps 2-4: Preparation of target compound-2

[0508] Following the synthetic method for target compound-1, target compound-2 was prepared by condensing M20 with M17 instead of M7, yielding a white solid powder with a yield of approximately 70%. MS (ESI) m / z: 1012.95 [M+2H] 2+ 676.22[M+3H] 3+ .

[0509] Example 3: Preparation of Compound-3

[0510] The specific synthesis steps are as follows.

[0511] Step 3-1: Preparation of M21

[0512] Following the synthetic method for compound M14, compound M21 was prepared by reverse condensation reaction of M13 with eczemabium methanesulfonate instead of MMAE. The resulting grayish-brown solid powder had a yield of approximately 99%. MS (EI) m / z: 977.44 [M+H] + .

[0513] Step 3-2: Preparation of M22

[0514] Following the synthetic method for compound M15, compound M22 was prepared by replacing M14 with M21 in diethylamine solution to remove the Fmoc protecting group, yielding an earthy gray solid powder with a yield of approximately 86%. MS (EI) m / z: 755.46 [M+H] + 378.04 [M+2H] 2+ .

[0515] Step 3-3: Preparation of M23

[0516] Following the synthetic method for compound M16, compound M23 was prepared by replacing M15 with M22 in a reverse condensation reaction with M10. The resulting light gray solid powder had a yield of approximately 96%. MS (EI) m / z: 738.95 [M+2H] 2+ .

[0517] Steps 3-4: Preparation of M24

[0518] Following the synthetic method for compound M17, compound M24 was prepared by replacing M16 with M23 in diethylamine solution to remove the Fmoc protecting group, yielding a light gray solid powder with a yield of approximately 92%. MS (EI) m / z: 627.99 [M+2H] 2+ 418.97 [M+3H] 3+ .

[0519] Steps 3-5: Preparation of target compound-3

[0520] Following the synthetic method for target compound-1, target compound-3 was prepared by condensing M24 with M7 instead of M17, yielding an off-white solid powder with a yield of approximately 67%. MS (ESI) m / z: 804.68 [M+2H] 2+ .

[0521] Example 4: Preparation of Compound-4

[0522] The specific synthesis steps are as follows.

[0523] Step 4-1: Preparation of target compound-4

[0524] Following the synthetic method for target compound-3, M20 was used instead of M7 in the condensation reaction with M24 to prepare target compound-4, a white solid powder with a yield of approximately 54%. MS (ESI) m / z: 871.40 [M+2H] 2+ 582.27 [M+3H] 3+ .

[0525] Example 5: Preparation of Compound-5

[0526] The specific synthesis steps are as follows.

[0527] Step 5-1: Preparation of target compound-5

[0528] The connector material, designated MCOSu, was purchased commercially and used directly (CAS No.: 55750-63-5; Bid Pharmaceuticals, catalog number: BD127233). Following the synthetic method for target compound-3, commercially available MCOSu was used to replace M7 in the condensation reaction with M24 to prepare target compound-5, a white solid powder with a yield of approximately 74%. MS (ESI) m / z: 724.64 [M+2H] 2+ .

[0529] Example 6: Preparation of Compound-6

[0530] The specific synthesis steps are as follows.

[0531] Step 6-1: Preparation of compound M25

[0532] Compound M11 (93 mg, 0.226 mmol) was dissolved in DMF (15 mL). While stirring, exatecan mesylate (100 mg, 0.1883 mmol), HATU (107.38 mg, 0.2824 mmol), and DIPEA (48.67 mg, 65.6 μL) were added sequentially at room temperature. The reaction was carried out overnight under nitrogen protection with stirring. After the reaction was complete, the solvent was removed by concentration under reduced pressure to obtain the crude product. Further purification by column chromatography yielded compound M25 as a light gray solid powder, 140 mg, with a yield of approximately 90%. MS (EI) m / z: 828.39 [M+H] + .

[0533] Step 6-2: Preparation of compound M26

[0534] Following the synthetic method for compound M15, compound M26 was prepared by replacing M14 with M25 and removing the Fmoc protecting group in the presence of diethylamine. The resulting compound was a grayish-brown solid powder with a yield of approximately 96%. MS (EI) m / z: 606.38 [M+H] + .

[0535] Step 6-3: Preparation of compound M27

[0536] Following the synthetic method for compound M16, compound M27 was prepared by replacing M15 with M26 in a reverse condensation reaction with M10, yielding a pale yellow solid powder with a yield of approximately 90%. MS (EI) m / z: 664.31 [M+2H] 2+ .

[0537] Step 6-4: Preparation of compound M28

[0538] Following the synthetic method for compound M17, compound M28 was prepared by replacing M16 with M27 in diethylamine solution to remove the Fmoc protecting group, yielding a pale yellow solid powder with a yield of approximately 95%. MS (EI) m / z: 1105.27 [M+H] + 553.05 [M+2H] 2+ .

[0539] Step 6-5: Preparation of target compound-6

[0540] Following the synthetic method for target compound-4, M28 was used instead of M24 in the condensation reaction with M20 to prepare target compound-6, a white solid powder with a pure product yield of approximately 60%. MS (ESI) m / z: 796.97 [M+2H] 2+ .

[0541] Example 7: Preparation of Compound-7

[0542] The specific synthesis steps are as follows.

[0543] Step 7-1: Preparation of target compound-7

[0544] Following the synthetic method for target compound-6, M7 was used instead of M20 in a condensation reaction with M28 to prepare target compound-7, a white solid powder with a pure product yield of approximately 74%. MS (ESI) m / z: 729.94 [M+2H] 2+ .

[0545] Example 8: Preparation of Compound-8

[0546] The specific synthesis steps are as follows.

[0547] Step 8-1: Preparation of target compound-8

[0548] Following the synthetic method for target compound-5, M17 was used instead of M24 in a condensation reaction with MCOSu to prepare target compound-8, a white solid powder with a pure product yield of approximately 68%. MS (ESI) m / z: 865.51 [M+2H] 2+ 887.45 [M+2Na] 2+ .

[0549] Example 9: Preparation of Compound-9

[0550] The specific synthesis steps are as follows.

[0551] Step 9-1: Preparation of compound M29

[0552] Following the synthetic method for compound M8, compound M29 was prepared by condensation reaction of (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxovalerate instead of (S)-4-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxovalerate, yielding an off-white solid powder with a pure product yield of approximately 90%. MS (EI) m / z: 480.27 [M+H] + 502.23 [M+Na] + .

[0553] Step 9-2: Preparation of compound M30

[0554] Following the synthetic method for compound M9, compound M30 was prepared by removing the double protecting group in trifluoroacetic acid solution using M29 instead of M8. The resulting product was a pale yellow oil with a crude product yield close to 100%. MS (EI) m / z: 324.14 [M+H] + 346.12 [M+Na] + .

[0555] Step 9-3: Preparation of compound M31

[0556] Compound M30 (6.39 g, 14.6 mM) was dissolved in tetrahydrofuran (THF, 130 mL). After dissolution with stirring at room temperature, triethylamine (TEA, 6.0 eq) was added dropwise. Then, a methanol (320 mL) solution of gluconic acid (7.8 g, 43.8 mM) was added, and the mixture was heated to 70 °C with continued stirring. After compound M30 was completely consumed, the reaction solution was concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography and lyophilized to obtain compound M31 as a white solid powder, with a purity of 52%. MS (EI) m / z: 502.02 [M+H] + .

[0557] Step 9-4: Preparation of compound M32

[0558] Following the synthetic method for compound M27, compound M32 was prepared by condensing M31 with M26 instead of M10, yielding an off-white solid powder with a purity yield of 84%. MS (EI) m / z: 1089.77 [M+H] + 544.95 [M+2H] 2+ .

[0559] Step 9-5: Preparation of compound M33

[0560] Compound M33 (150 mg, 0.138 mM) was dissolved in MeOH (15 mL), and a catalytic amount of Pd / C (w / w 0.2 eq) was added. The Cbz protecting group was removed under a H2 atmosphere. After the reaction was complete, insoluble matter was removed by filtration, and the filtrate was directly concentrated under reduced pressure to obtain compound M33 as an off-white solid powder, with a crude product yield of 88%. MS (EI) m / z: 955.53 [M+H] + ; 478.01 [M+2H] 2+ .

[0561] Step 9-6: Preparation of target compound-9

[0562] Following the synthetic method for target compound-7, M33 was used instead of M28 in the condensation reaction with M7 to prepare target compound-9, a white solid powder with a pure product yield of approximately 54%. MS (ESI) m / z: 654.71 [M+2H] 2+ ;655.61[M+2H] 2+ .

[0563] Example 10: Preparation of Compound-10

[0564] The specific synthesis steps are as follows.

[0565] Step 10-1: Preparation of compound M34

[0566] Following the synthetic method for compound M10, compound M34 was prepared by reacting glucose and sodium cyanoborohydride with M30 instead of M9. The resulting compound was a white solid powder with a pure product yield of approximately 74%. MS (ESI) m / z: 652.30 [M+H].

[0567] Step 10-2: Preparation of compound M35

[0568] Following the synthetic method for compound M33, M34 was used instead of M32 in a hydrogenation reaction under palladium-carbon catalysis to remove the Cbz protecting group, yielding compound M35, a white solid powder with a yield close to 100%. The product was directly used in the next reaction. MS (ESI) m / z: 518.04 [M+H].

[0569] Step 10-3: Preparation of compound M36

[0570] Compound M35 (397 mg, 0.767 mM) and Fmoc-Val-NHS (402 mg, 0.920 mM) were dissolved in a mixture of acetonitrile and water (10 mL + 10 mL). A catalytic amount of N-methylmorpholine (NMM) was added dropwise, and the reaction mixture was stirred overnight at room temperature. After the reaction was complete, the reaction solution was concentrated and directly purified by C18 reversed-phase chromatography. The purified compound, M36, was obtained by lyophilization as a white solid powder with a purity of 95%. MS (ESI) m / z: 839.05 [M+H] + .

[0571] Step 10-4: Preparation of compound M37

[0572] Following the synthetic method for compound M25, compound M37 was prepared by condensing it with Exateacan using M36 instead of M11. The resulting product was a grayish-brown solid powder with a purity yield of 50%. MS (ESI) m / z: 628.81 [M+2H] 2+ .

[0573] Step 10-5: Preparation of compound M38

[0574] Following the synthetic method for compound M15, compound M38 was prepared by removing the Fmoc protecting group in diethylamine solution using M37 instead of M14. The resulting product was a grayish-brown solid powder with a purity yield of 75%. MS (ESI) m / z: 517.84 [M+2H] 2+ .

[0575] Step 10-6: Preparation of target compound-10

[0576] Following the synthetic method for target compound-7, M38 was used instead of M28 in a condensation reaction with M7 to prepare target compound-10, a pale yellow solid powder with a pure product yield of approximately 68%. MS (ESI) m / z: 1034.47 [M+H] + 694.37 [M+2H] 2+ .

[0577] Example 11: Preparation of Compound-11

[0578] The specific synthesis steps are as follows.

[0579] Step 11-1: Preparation of compound M39

[0580] Following the synthetic method for compound M35, M31 was used instead of M34 in a hydrogenation reaction under palladium-carbon catalysis to remove the Cbz protecting group, yielding compound M39, a white solid powder with a crude product yield of 99%. The product was directly used in the next reaction. MS (ESI) m / z: 368.21 [M+H].

[0581] Step 11-2: Preparation of compound M40

[0582] Following the synthetic method for compound M36, compound M40 was prepared by acylation condensation reaction with Fmoc-Val-NHS using M39 instead of M35. The compound was a white solid powder with a purity yield of 88%. MS (ESI) m / z: 689.32 [M+H] + 711.30 [M+Na] + .

[0583] Step 11-3: Preparation of compound M41

[0584] Following the synthetic method for compound M37, compound M41 was prepared by condensing it with Exateacan using M40 instead of M36. The resulting product was a grayish-brown solid powder with a yield of 73%. MS (ESI) m / z: 1106.43 [M+H]+ 553.73 [M+2H] 2+ .

[0585] Step 11-4: Preparation of compound M42

[0586] Following the synthetic method for compound M38, compound M42 was prepared by removing the Fmoc protecting group in a diethylamine solution using M41 instead of M37. The resulting grayish-brown solid powder had a yield of 68%. MS (ESI) m / z: 884.41 [M+H] + .

[0587] Step 11-5: Preparation of target compound-11

[0588] Following the synthetic method for target compound -10, M42 was used instead of M38 in the condensation reaction with M7 to prepare target compound -11, an off-white solid powder with a pure product yield of approximately 67%. MS (ESI) m / z: 619.23 [M+2H] 2+ 641.21[M+Na] + .

[0589] Example 12: Preparation of Compound-12

[0590] The specific synthesis steps are as follows.

[0591] Step 12-1: Preparation of target compound-12

[0592] Following the synthetic method for target compound -10, M20 was used instead of M7 in the condensation reaction with M38 to prepare target compound -12, an off-white solid powder with a pure product yield of approximately 56%. MS (ESI) m / z: 761.29 [M+2H] 2+ 783.27 [M+2Na] 2+ .

[0593] Example 13: Preparation of Compound-13

[0594] The specific synthesis steps are as follows.

[0595] Step 13-1: Preparation of target compound-13

[0596] Following the synthetic method for target compound -10, MCOsu was used to replace M7 in the condensation reaction with M38 to prepare target compound -13, a white solid powder with a pure product yield of approximately 70%. MS (ESI) m / z: 614.29 [M+2H] 2+ 636.25 [M+2Na] 2+ .

[0597] Example 14: Preparation of Compound-14

[0598] The specific synthesis steps are as follows.

[0599] Step 14-1: Preparation of target compound-14

[0600] Following the synthetic method for target compound -11, M20 was used instead of M7 in the condensation reaction with M42 to prepare target compound -14, a white solid powder with a pure product yield of approximately 66%. MS (ESI) m / z: 686.25 [M+2H] 2+ 708.23 [M+2Na] 2+ .

[0601] Example 15: Preparation of Compound-15

[0602] The specific synthesis steps are as follows.

[0603] Step 15-1: Preparation of target compound-15

[0604] Following the synthetic method for target compound -11, target compound -15 was prepared by condensation reaction of M7 and M42 using MCOSu instead of M7, yielding an off-white solid powder with a pure product yield of approximately 66%. MS (ESI) m / z: 1077.46 [M+H] + 1099.45 [M+Na] + .

[0605] Example 16: Preparation of Compound-16

[0606] The specific synthesis steps are as follows.

[0607] Step 16-1: Preparation of target compound-16

[0608] MC-PEG4-OSu (Chinese Patent Application No.: 202410068212, filed January 17, 2024; Compound M66; CAS No.: 1325208-25-0) was prepared according to the previously reported synthetic method of the inventors. Following the synthetic method of target compound -10, MC-PEG4-OSu was used to replace M7 in the condensation reaction with M38 to prepare target compound -16, a pale yellow solid powder, with a pure product yield of approximately 54%. MS (ESI) m / z: 681.31 [M+2H] 2+ 703.29 [M+2Na] 2+ .

[0609] Example 17: Preparation of Compound-17

[0610] The specific synthesis steps are as follows.

[0611] Step 17-1: Preparation of target compound-17

[0612] Following the synthetic method for target compound -11, MC-PEG4-OSu was used to replace M7 in the condensation reaction with M42 to prepare target compound -17, a white solid powder with a pure product yield of approximately 66%. MS (ESI) m / z: 606.26 [M+2H] 2+ 628.24 [M+2Na] 2+ .

[0613] Example 18: Preparation of Compound-18

[0614] The specific synthesis steps are as follows.

[0615] Step 18-1: Preparation of target compound-18

[0616] Following the synthetic method for target compound -7, MC-PEG4-OSu was used to replace M7 in a condensation reaction with M28 to prepare target compound -18, a white solid powder with a pure product yield of approximately 62%. MS (ESI) m / z: 716.83 [M+2H] 2+ 738.81 [M+2Na] 2+ .

[0617] Example 19: Preparation of Compound-19

[0618] The specific synthesis steps are as follows.

[0619] Step 19-1: Preparation of target compound-19

[0620] Following the synthetic method for target compound-1, MC-PEG4-OSu was used to replace M7 in a condensation reaction with M17 to prepare target compound-19, a white solid powder with a pure product yield of approximately 68%. MS (ESI) m / z: 932.52 [M+2H] 2+ 954.51 [M+2Na] 2+ .

[0621] Example 20: Preparation of Compound-20

[0622] The specific synthesis steps are as follows.

[0623] Step 20-1: Preparation of target compound-20

[0624] Following the synthetic method for target compound-3, MC-PEG4-OSu was used to replace M7 in the condensation reaction with M24 to prepare target compound-20, a white solid powder with a pure product yield of approximately 53%. MS (ESI) m / z: 791.35 [M+2H] 2+ 813.33 [M + 2Na] 2+ .

[0625] Example 21: Preparation of Compound-21

[0626] The specific synthesis steps are as follows.

[0627] Step 21-1: Preparation of target compound-21

[0628] Purchased Mal-C3-PEG4-OSu (SIGMA-ALDRICH, product number 712582, CAS No.: 756525-99-2) was directly used in the synthesis reaction. Following the synthesis method of target compound -6, Mal-C3-PEG4-OSu was used to replace M7 in the condensation reaction with M28 to prepare target compound -21, a pale yellow solid powder, with a pure product yield of approximately 49%. MS (ESI) m / z: 752.33 [M+2H] 2+ 774.32[M+2Na] 2+ .

[0629] Example 22: Preparation of compound-22

[0630] The specific synthesis steps are as follows.

[0631] Step 22-1: Preparation of target compound-22

[0632] Following the synthetic method for target compound-1, target compound-22 was prepared by condensing M7 with M17 using Mal-C3-PEG4-OSu instead of M7, yielding a white solid powder with a pure product yield of approximately 68%. MS (ESI) m / z: 968.04 [M+2H] 2+ 990.02 [M+2Na] 2+ .

[0633] Example 23: Preparation of compound-23

[0634] The specific synthesis steps are as follows.

[0635] Step 23-1: Preparation of target compound-23

[0636] Following the synthetic method for target compound -11, target compound -23 was prepared by condensing M7 with M42 using Mal-C3-PEG4-OSu instead of M7, yielding an off-white solid powder with a pure product yield of approximately 65%. MS (ESI) m / z: 641.78 [M+2H] 2+ 663.75 [M+2Na] 2+ .

[0637] Example 24: Preparation of Compound-24

[0638] The specific synthesis steps are as follows.

[0639] Step 24-1: Preparation of target compound-24

[0640] Following the synthetic method for target compound -10, Mal-C3-PEG4-OSu was used to replace M7 in a condensation reaction with M38 to prepare target compound -24, a white solid powder with a pure product yield of approximately 56%. MS (ESI) m / z: 716.83 [M+2H] 2+ 738.81 [M+2Na] 2+ .

[0641] Example 25: Preparation of Compound-25

[0642] The specific synthesis steps are as follows.

[0643] Step 25-1: Preparation of target compound-25

[0644] Following the synthetic method for target compound-3, target compound-25 was prepared by condensing M7 with M24 using Mal-C3-PEG4-OSu instead of M7, yielding an off-white solid powder with a pure product yield of approximately 55%. MS (ESI) m / z: 826.87 [M+2H] 2+ 848.85 [M+2Na] 2+ .

[0645] Example 26: Preparation of antibody-drug conjugates

[0646] In the preparation of ADC, the antibodies selected for ADC were either the humanized IgG1 antibody against HER-2 (trastuzumab) or the humanized IgG antibody against B7-H3 (CD276) (CE4-Z3), in order to verify the conjugation performance, drug-likeness, and in vitro and in vivo pharmacodynamic characteristics of the novel linker-payload prepared.

[0647] Step 36-1: General preparation method of DAR4 ADC

[0648] ① Antibody replacement: Before conjugation, the selected antibody (IgG) is desalted using an AKTA system with a G25 dextran gel column, and the protein is replaced in the conjugation buffer (PBS: 20mM; EDTA: 2mM; pH 6.5–8.0; or L-HIs: 20mM; EDTA: 2mM; pH 6.5–8.0). The absorbance of the protein is measured using a UV spectrophotometer, and the antibody concentration after buffer replacement is calculated using the extinction coefficient method. If the antibody concentration is lower than the conjugation concentration, ultrafiltration is performed to concentrate the protein and increase the protein concentration.

[0649] ② Preparation of the conjugation reaction solution: Based on the required amount of conjugated antibody (1 eq), use a pipette to accurately transfer the corresponding conjugation system buffer to make the antibody concentration the initial conjugation concentration, usually 1 to 10 mg / mL.

[0650] ③ Antibody reduction: Add 2.0–2.5 eq of TCEP·HCl solution (1.0 mg / mL–5.73 mg / mL) to the reaction vial containing the antibody solution while stirring slowly; after the addition is complete, stir slowly at room temperature for 60–180 min.

[0651] ④ Antibody conjugation: Calculate the volume of organic solvent (DMAC or DMSO) to be added, ensuring it comprises 5%–15% of the total volume (usually ≤10%). Simultaneously, calculate the mass of the linker-payload to be added; typically, a slight excess of the linker-payload (usually 8 eq) is required. Then calculate the concentration of the organic solution containing the linker-payload. After accurately preparing the linker-payload solution, slowly add it dropwise to the reduced antibody reaction solution. Continue stirring slowly at room temperature for 0.25–1.0 h, depending on the specific conjugation situation.

[0652] ⑤ Quenching of the reaction: After the reaction solution reaches the predetermined coupling time, add an excess of water-soluble small molecule N-acetylcysteine ​​(NAC) solution containing reducing thiol groups (1.0-3.26 mg / mL), and stir slowly to continue the reaction for 15-60 min.

[0653] ⑥ ADC product purification: After the coupling reaction is quenched, the reaction solution is first filtered, and then desalted using an AKTA system with a G25 or G50 dextran gel column. The first part (about 80%) of the component eluent is collected, concentrated again by ultrafiltration, aseptically filtered, and then aliquoted. Except for a portion of the ADC sample reserved for analysis which is stored at 4°C for a short period of time, the other ADC products are stored at -80°C for later use.

[0654] Step 36-2: General fabrication method of DAR8 ADC

[0655] Following the procedure in step 36-1, adjust the amount of TCEP·HCl in step ③ (antibody reduction) to 4.0–6.0 eq, and adjust the amount of NAC in step ④ (antibody coupling) (linker-effective loading) and step ⑤ (reaction quenching) to 8–12 eq. An ADC product with DAR≈8.0 was obtained.

[0656] Step 36-3: General Method for DAR Value Analysis of ADC

[0657] ① Analysis of DAR value of ADC with MMAE as effective load

[0658] ADCs with different drug concentrations for each antibody were separated at room temperature using a butyl HIC column (TSK gel butyl NPR 4.6 × 35 mm 2.5 μm, Tosoh Bioscience). HIC was also performed on an Agilent 1260 Infinity II HPLC system or a Shimadzu HPLC system with UV detection at 280 nm. Mobile phase A consisted of 1.5 mmol / L (NH4)2SO4 and 50 mmol / L K2HPO4 at pH 7.0, and mobile phase B consisted of 21.3 mmol / L KH2PO4, 28.6 mmol / L K2HPO3, and 25% (v / v) isopropanol at pH 7.0. The gradient program was as follows: B%: 0% to 25% (0–1 min, 0.8 mL / min), 25% (1–3 min, 0.6 mL / min). The DAR value of the ADC being tested is calculated by integrating and weighting the chromatographic peak areas corresponding to DAR=0, DAR=2, DAR=4, DAR=6, and DAR=8.

[0659] ② DAR value analysis of the ADC with Dx-8951f as the effective load

[0660] The absorbance of the ADC under test was measured at wavelengths of 280 nm and 360 nm using a UV spectrophotometer, with three parallel measurements performed. The average absorbance at each wavelength was then calculated. Since the antibody does not exhibit UV absorption at the characteristic absorption wavelength of the linker-payload (360 nm), the relationship between the mass concentration of the linker-payload and A360 (a linear equation in one variable), as well as the multiple relationship between A360 and A280, was calculated using a standard curve method. The mass concentration of the linker-payload in the ADC and its A280 value were then calculated using the calculated A360. Finally, according to Beer-Lambert's law, the total absorbance at any given wavelength is equal to the sum of the absorbances of all photosensitive chemicals present in the system at that wavelength. mAb =A平均 -A 连接子-有效荷载 Calculate the absorbance value A of the antibody at A280. mAb Finally, the DAR value of the ADC was calculated by determining the molar ratio of linker-effective payload to antibody in the solution.

[0661] ③ LC-MS method for ADC-DAR value analysis

[0662] Take 100 μg of ADC or naked antibody sample, add 1 μl of PNGaseF 500U, and digest overnight at 37℃ to obtain the sample to be tested. LC-MS / MS parameter settings: The LC system used was ACQUITY UPLC H-Class (Waters), and the column was ACQUITY UPLC Protein, BEH SEC. The column was 1.7 μm, 2.1 mm × 100 mm, with a column temperature of 25 °C. The mobile phase was 100 mM ammonium acetate aqueous solution, with isocratic elution and a flow rate of 0.1 ml / min. The mass spectrometry detection system was a Xevo G2-XS Qtof (Waters), with positive ion detection mode and full scan mode. Data acquisition was performed using MassLynx 4.1 (Waters) software, followed by MaxEnt I deconvolution processing. The model parameter settings were a resolution of 2-3.5 Da. The minimum intensity ratio was set to 60%, and the output resolution was set to 1 Da. The algorithm iteration parameter was set to 20. The DAR value of the tested ADC was calculated by weighting the TIC peak heights corresponding to DAR=0, DAR=2, DAR=4, DAR=6, and DAR=8 of the deconvolutioned ADC.

[0663] Step 36-4: General Methods for Polymerization Analysis of ADCs

[0664] Aggregation of ADC products was evaluated by size exclusion chromatography, performed on an Agilent 1260 Infinity II HPLC system or a Shimadzu HPLC system with UV detection at 280 nm. The column used was a TSKgel G3000SWXL column (Tosoh Bioscience). Samples were injected at loadings of 20–50 μg. The mobile phase consisted of 200 mmol / L sodium phosphate and 150 mmol / L sodium chloride (pH 7.0). Additionally, 10% (v / v) isopropanol was added to the mobile phase to minimize secondary hydrophobic interactions with the stationary phase and to prevent bacterial growth. The column temperature was set to room temperature. The peak areas of the monomer, fragment, and polymer peaks corresponding to the ADC under SEC chromatography were integrated, and the percentage of monomer content in the ADC was calculated using area normalization.

[0665] The structures of the fabricated ADCs are shown in Table 1:

[0666] Table 1

[0667] Example 27: Hydrophilicity / Hydrophobicity Study of Antibody-Drug Conjugates

[0668] To directly compare the hydrophilicity / hydrophobicity differences between the ADC based on the novel hydrophilic linker-payload in this invention and the ADC based on the traditional linker-payload, this invention uses the most mainstream DS-8201 (trastuzumab) on the market as a control and directly compares its hydrophobic chromatography (HIC) performance with the structurally representative ADC-7 in this invention.

[0669] Molecules with higher hydrophilicity exhibit shorter retention times. HPLC-HIC results showed that, with the same DAR value (DAR=8), the retention time of the ADC-7 associated with this invention was 19.10 min, while the retention time of DS-8201 was 26.31 min. The ADC-7 of this invention exhibits significantly superior hydrophilicity and is closer to the retention time of the naked anti-trastuzumab. This indirectly reflects that even at DAR=8, the ADC-7 of this invention is almost identical to the naked antibody in terms of hydrophilicity (Figure 1).

[0670] Generally, molecules with higher hydrophilicity have lower protein aggregation. Furthermore, this invention compared the product purity of DS-8201 with that of ADC-7 under the same vigorous coupling conditions. The results (Table 2) show that in the PBS coupling system, ADC-7 has higher SEC purity and a lower aggregate content than DS-8201, demonstrating the improved drug-forming properties resulting from the hydrophilic group in this invention.

[0671] Table 2

[0672] Example 28: Stability Study of ADC

[0673] This invention evaluated the in vitro stability of ADCs based on novel hydrophilic groups and antibody-conjugated drug connectors. Using DS-8201 as a control, and ADC-1, ADC-4, and ADC-7 as representative ADC molecules of this invention, stability studies were conducted in monkey and mouse plasma, respectively. The main parameter evaluated was ADC connector stability, i.e., the change in the residual concentration of the antibody-conjugated drug (acDrug) with plasma incubation time.

[0674] The experimental results (Figures 2 and 3) show that ADC-1, ADC-4, and ADC-7 based on the present invention exhibit significantly improved stability in monkey and mouse plasma compared to DS-8201 based on conventional conjugation technology (P<0.001). This indicates that the ADCs of the present invention will have lower payload off-target rates and higher payload delivery efficiency in plasma after administration.

[0675] Example 29: In vitro cytotoxicity study of ADC

[0676] This invention evaluated the in vitro cytotoxicity of novel linker-payload-based ADCs. First, a control ADC, Trast-vc-MMAE (DAR≈4), was prepared using Trastuzumab conjugated with commercially available vc-MMAE (Haoyuan Pharmaceuticals, catalog number: HY-15575; CAS No.: 646502-53-6). Simultaneously, using staurosporine as a control, the cytotoxicity of several Trastuzumab-based ADCs on the HER2-positive gastric cancer cell line NCI-N87 was evaluated. The results (see Table 3) showed that the ADCs related to this invention (ADC-1, ADC-2, ADC-3, ADC-4, ADC-5, ADC-6, ADC-7, ADC-10, ADC-11), as well as the control ADC (Trast-vc-MMAE) and the control small molecule drug staurosporine, all exhibited extremely high activity (10-10). -9 (mol / L level).

[0677] Table 3

[0678] Meanwhile, the activity of the aforementioned ADCs and related controls was also tested on the MCF-7 breast cancer cell line with low HER2 antigen expression. The results showed (see Table 4) that the ADCs related to this invention (ADC-1, ADC-2, ADC-3, ADC-4, ADC-5, ADC-6, ADC-7, ADC-10, ADC-11) and the control ADC (Trast-vc-MMAE) did not exhibit significant activity (IC50 > 100 nmol / L), but the small molecule drug astrocytocin still showed significant cell inhibitory activity (10 nmol / L). -9 (mol / L level).

[0679] Table 4

[0680] The above cytotoxicity tests demonstrate that the ADC of the present invention has ideal in vitro tumor cell inhibitory activity, while its cell-killing performance has ideal antigen selectivity.

[0681] Example 30: In vivo pharmacodynamic study of ADC in a mouse model

[0682] To verify the in vivo efficacy characteristics of the novel Linker-Payload-based ADCs, this invention first verified the efficacy of these ADCs in a mouse model using a tumor xenograft CDX model of the HER2-positive gastric cancer cell line NCI-N87.

[0683] Female Balb / c-nude mice aged 6–8 weeks were used as test animals and housed in an environment with a temperature of 20–26°C and a humidity of 40–70%. Each test group / box was housed separately. NCI-N87 cells were passaged in MEM (+0.01 mM NEAA) + 10% FBS medium. Cells in the exponential growth phase were collected, resuspended to an appropriate concentration, and then used for subcutaneous tumor inoculation in mice. 5 × 10⁶ cells were subcutaneously inoculated into the right back of each experimental mouse. 6 NCI-N87 cells were used until the tumor grew to an average size of approximately 150 mm. 3 At that time, based on tumor size and mouse weight, a randomized grouping design was used (using StudyDirector). TM The software (version 3.1.399.19, supplier: Studylog Systems, Inc., S. San Francisco, CA, USA) was used to group mice. Mice were then grouped and administered the drug at the prescribed dose on the same day after grouping. The administration volume was calculated based on V = 10 μL / g. Tumor volume was expressed as V (mm²). 3 ) = 1 / 2 × (major axis × minor axis) 2 The tumor volume and mouse weight were measured twice weekly. The effects of the test drug on the animals' normal behavior were observed and recorded each time tumor volume and mouse weight were measured. Data are expressed as mean ± SD. Unpaired two-tailed t-tests were used for statistical analysis, with a significance level set at p < 0.05. GraphPad software (Version 8.0.2, La Jolla, CA, USA) was used for statistical analysis.

[0684] The results (Figure 4) showed that the ADCs 1, ADC 4, and ADC 7 related to this invention achieved complete tumor regression with a single dose of 1.5 mg / kg. Furthermore, they all showed significant differences compared to the solvent vehicle group (P < 0.0001). During the treatment and observation period after administration, the test animals showed a steady increase in body weight, preliminarily demonstrating the safety of the tested ADCs at therapeutic doses (Figure 5). In vivo pharmacodynamic data demonstrated that the ADCs developed using the Linker-Payload related to this invention possess significant in vivo pharmacodynamic characteristics.

[0685] Similarly, this invention evaluated the in vivo pharmacodynamics of novel Linker-Payload-based ADCs in a mouse xenograft CDX model of JIMT-1 breast cancer cell line with low HER2 antigen expression. The results (Figure 6) showed that the ADCs-1, ADC-4, and ADC-7 associated with this invention, at a dose of 3.0 mg / kg, resulted in partial tumor regression after a single administration (the proportions of complete tumor regression were 4 / 5, 3 / 5, and 5 / 5, respectively). Furthermore, these regressions were significantly different from those in the solvent vehicle group (P < 0.0001). Likewise, during the observation period after administration, the test animals showed a steady increase in body weight, further demonstrating the safety of the tested ADCs at therapeutic doses (Figure 7).

[0686] Example 31: Safety study of anti-B7-H3 ADC in mouse model

[0687] This invention further evaluates the maximum tolerated dose (MTD) of ADCs based on novel Linker-Payloads. The antibody used in the test ADCs was the inventors' previously published humanized anti-CD276 antibody CE4-Z3 (Chinese Patent Application No.: 2024100694957, filed January 17, 2024; humanized antibody CE4-Z3). The Linker-Payload consisted of representative compounds -4 and -7, which were conjugated to obtain ADCs with DAR≈8, namely ADC-26 and ADC-27. The transgenic animals B-hB7-H3(C57BL6-Cd276tm1(CD276) / Bcgen were purchased from Biocytogen (Beijing, CN). The dosing regimen was as follows: 100 mg / kg was administered on day 0, followed by a further 200 mg / kg on day 7. Weight changes, adverse reactions, and mortality were observed in the test animals after administration. Blood samples were collected from mice to assess hematological toxicity before the end of the safety study.

[0688] The results (Figure 8) showed that ADC-26 and ADC-27, related to this invention, still exhibited good safety characteristics after two high-dose administrations. After the first administration of 100 mg / kg, the average body weight of all animals in the ADC-26 test group decreased by 7.05% on day 3 and essentially recovered to pre-administration weight before the second administration; the body weight of all animals in the ADC-27 test group continued to increase, with an average increase of 4.78% before the second administration (day 7). On day 7 of the experiment, after administering 200 mg / kg of ADC-26 and ADC-27 to both groups of animals respectively, the average body weight of all animals in the ADC-26 test group decreased to its maximum (12.3%) on day 12 and essentially recovered to pre-administration weight before the end of the experiment (day 20); the body weight of all animals in the ADC-27 test group continued to increase after minor fluctuations, with an average increase of 5.76% by the end of the experiment.

[0689] Nine days after the second dose of 200 mg / kg (day 16 of the experiment), blood samples were collected from the test mice for hematological analysis. Hematological analysis showed that, compared with the hematological parameters in the Biocytogen C57BL6-Cd276tm1(CD276) / Bcgen mouse manual, the test animals did not exhibit irreversible hematological toxicity (recovered hematological data are not shown).

[0690] During the aforementioned tolerance dose trials, none of the test animals experienced drug-related deaths following two administrations of high doses. These data indicate that the maximum tolerated dose (MTD) of ADC-26 in the aforementioned humanized transgenic mice was 200 mg / kg, while the MTD of ADC-27 in this mouse species exceeded 200 mg / kg.

[0691] The above safety evaluation data collectively demonstrate that the novel Linker-Payload provided in this invention exhibits good safety and a high maximum tolerated dose (MTD) when developed for use in ADCs.

[0692] The above description, in conjunction with specific preferred embodiments, provides a further detailed explanation of the present invention. It should not be construed that the specific implementation of the present invention is limited to these descriptions. For those skilled in the art, various simple deductions or substitutions can be made without departing from the concept of the present invention, and all such modifications and substitutions should be considered within the scope of protection of the present invention.

Claims

1. A compound of formula (I), or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof: in, U is a linker that can react with thiol groups; W1 is -W 1a -W 1b -; W 1a Selected from chemical bonds, -(CH2) m24 -、-(OCH2CH2) n15 -or-(CH2CH2O) n16 -; W 1b Selected from chemical bonds, -O-, -S-, -NR b -、-C(O)O-、-C(O)NR b -、-OC(O)-、-NR b -C(O)-, -S(O) p O-, -S(O) p NR b -、-OS(O) p -、-NR b -S(O) p -or-NR b -S(O) p NR b -; Where p = 1 or 2; L1 represents a chemical bond or -(CH2). m1 -(OCH2CH2) n1 -(CH2CH2O) n2 -(CH2) r1 -(L) q -(CH2) r2 -(OCH2CH2) n3 -(CH2CH2O) n4 -(CH2) m2 -; Where -L- is selected from -O-, -NR b -、-C(O)NR b -、-C(O)O-、-NR b -C(O)-、-OC(O)-、-C 3-8 Cycloalkyl-, -3-8-membered heterocyclic-, -C 6-10 arylene- or -5-10 arylene-arylene; Each m1, m2, m24, n1, n2, n3, n4, n15, n16, r1, and r2 is independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; q = 0, 1, or 2; W2 is selected from chemical bonds, -O-, -S-, and -NR. b -or -C(O)-; L2 is selected from the following amino acid residues or oligopeptide residues consisting of 2 to 10 amino acids, wherein the amino acids are selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, and wherein the amino acids are optionally substituted by 1, 2, 3, 4, 5, or 6 R4 residues, and at least one amino acid is replaced by R4. H replace; The N-terminus of the amino acid residue or oligopeptide residue is linked to W2, and the C-terminus is linked to L3; R H It is -H1-H2-NR2R3; Wherein, H1 is selected from chemical bonds, -O-, -S-, -NR1-, -C(O)-, -S(O)- and -S(O)2-; H2 is -(CH2) a - where 1, 2 or 3 methylene units are optionally and independently replaced by -O-, -S- or -NR1-; a = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; R1 is selected from H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups; R2 and R3 are each independently selected from H and C. 1-6 Alkyl, C 1-6 The alkyl halogroup and the hydrophilic polyhydroxy alcohol group, or polyethylene glycol or a structural variant thereof, and at least one of R2 and R3 is a hydrophilic polyhydroxy alcohol group; R4 is independently selected from D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl, C 1-6 Halogenated alkyl groups, polyethylene glycol, polysarcosine, pentose sugars, hexose sugars, sulfonic acid groups, methanesulfonyl groups, phosphoric acid groups, phosphite groups, quaternary ammonium salts, or groups selected from the following: L3 is selected from chemical bonds or the following structures: NH is connected to L2, and C(O) is connected to D; R5 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl or C 1-6 Halogenated alkyl groups; t = 0, 1, 2, 3 or 4; R6 is selected from H, D is the active compound, selected from drugs, cytotoxins, detection reagents, diagnostic reagents, or targeting carriers; R a R b and R c Independently selected from H and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-10 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 aryl or 5-10 heteroaryl; or R b and R c Together with the N atoms they are connected to, they form 3-10 membered heterocyclic groups; The aforementioned groups may optionally be substituted with one or more deuterium groups, up to and including complete deuteration.

2. The compound of formula (I) of claim 1, or its prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, U is selected from single-reactive adapters and bridged double-reactive adapters capable of reacting with thiol groups; preferably selected from: Preferred selection Preferred Among them, R9 is independently selected from C 1-6 Alkyl or C 1-6 Halogenated alkyl groups, preferably C 1-4 Alkyl or C 1-4 The alkyl group is haloalkyl, preferably methyl; X is a halogen, preferably Cl, Br or I, preferably I.

3. A compound of formula (I) of claim 1 or 2, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, W1 is -W 1a -W 1b -; W 1a Selected from chemical bonds, -(CH2) m24 -、-(OCH2CH2) n15 -or-(CH2CH2O) n16 -, preferably chemical bonds and -(CH2) m24 -; Preferred chemical bonds; W 1b Selected from -C(O)O-, -C(O)NR b -、-OC(O)- or -NR b -C(O)-, preferably -C(O)O- or -C(O)NR b -; Wherein m24, n15, n15 are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 1, 2, 3, 4, 5 or 6.

4. A compound of formula (I) according to any one of claims 1-3, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, L1 is selected from chemical bonds, -(CH2) m1 -(CH2CH2O) n1 -(CH2) r1 -L-(CH2) r2 -(CH2CH2O) n2 -(CH2) m2 -or-(CH2) m3 -(OCH2CH2) n3 -(CH2) r3 -L-(CH2) r4 -(OCH2CH2) n4 -(CH2) m4 -; Preferably, L1 is selected from chemical bonds, -(CH2CH2O). n5 -(CH2) r5 -L-(CH2) m5 -、-(OCH2CH2) n6 -(CH2) r6 -L-(CH2) m6 -、-(CH2) m7 -L-(CH2CH2O) n7 -(CH2) r7 -or-(CH2) m8 -L-(OCH2CH2) n8 -(CH2) r8 -; Preferably, L1 is selected from chemical bonds, -(CH2). m9 -(CH2CH2O) n9 -(CH2) r9 -or-(CH2) m10 -(OCH2CH2) n10 -(CH2) r10 -; Preferably, L1 is selected from chemical bonds, -(CH2CH2O). n11 -(CH2) m11 -、-(CH2) m12 -(CH2CH2O) n12 -、-(OCH2CH2) n13 -(CH2) m13 -or-(CH2) m14 -(OCH2CH2) n14 -; Preferably, L1 is selected from chemical bonds, -(CH2). m15 -O-(CH2) m16 -、-(CH2) m17 -O-、-(CH2) m18 -NH-, -O-(CH2) m19 -or-NR b -(CH2) m20 - Preferably, L1 is selected from chemical bonds, -(CH2). m21 -、-L-、-(CH2) m22 -L- or -L-(CH2) m23 -; Preferably, L1 is selected from chemical bonds, -(CH2CH2O). n11 -(CH2) m11 -or-(CH2) m21 -; Where m1, m2, m3, m4, m5, m6, m7, m8, m9, m10, m11, m12, m13, m14, m15, m16, m17, m18, m19, m20, m21, m22, and m23 are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n1, n2, n3, n4, n5, n6, n7, n8, n9, n10, n11, n12, n13, n14 are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; r1, r2, r3, r4, r5, r6, r7, r8, r9, r10 are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

5. A compound of formula (I) according to any one of claims 1-4, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, -L- is selected from -C(O)NR b -、-C(O)O-、-NR b -C(O)- or -OC(O)-.

6. A compound of formula (I) according to any one of claims 1-5, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, W2 is selected from chemical bonds or -C(O)-.

7. A compound of formula (I) according to any one of claims 1-6, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, L2 is selected from the following amino acid residues or oligopeptide residues consisting of 2 to 5 amino acids, wherein the amino acids are selected from phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, and wherein the amino acid is optionally substituted by 1, 2, 3, or 4 R4 residues, and one of the amino acids is substituted by 1 R4 residue. H replace; Preferably, L2 is selected from dipeptide, tripeptide, or tetrapeptide (preferably dipeptide or tripeptide) residues composed of the following amino acids, wherein the amino acids are selected from phenylalanine, isoleucine, leucine, valine, alanine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, citrulline, aspartic acid, and glycine, and wherein the amino acids are optionally substituted by 1, 2, 3, or 4 R4 residues, and one of the amino acids is substituted by 1 R4 residue. H replace; Preferably, L2 is selected from valine-glutamic acid, valine-glutamine, valine-aspartic acid, valine-asparagine, glutamic acid-valine-alanine, glutamine-valine-alanine, aspartic acid-valine-alanine, and asparagine-valine-alanine, optionally substituted with 1, 2, 3, or 4 R4, and one of the amino acids is replaced by 1 R4. H replace; Preferably, R H The substituted amino acids are selected from glutamic acid, glutamine, aspartic acid and asparagine, with glutamic acid and glutamine being preferred, and glutamic acid being even more preferred; Preferably, L2 is either -P1-AA1- or -AA2-P1-; where AA1 is connected to L3 and AA2 is connected to W2; P1 is independently selected from glutamic acid, glutamine, aspartic acid, and asparagine, and is determined by one R H replace; AA1 is selected from the following amino acid residues or oligopeptide residues consisting of 2-3 (preferably 2) or fewer amino acids; wherein the amino acid is selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably valine, alanine, leucine, and isoleucine, preferably valine and alanine, and preferably valine-alanine; and wherein the amino acid is optionally substituted by 1, 2, 3, 4, 5, or 6 (preferably 1, 2, 3, or 4) R4 residues; AA2 is selected from the following amino acid residues or oligopeptide residues consisting of 2-3 or fewer amino acids; wherein the amino acid is selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably the following amino acid residues: valine, alanine, leucine, and isoleucine, with valine being the most preferred; and the amino acid is optionally substituted by 1, 2, 3, 4, 5, or 6 (preferably 1, 2, 3, or 4) R4 residues.

8. A compound of formula (I) according to any one of claims 1-7, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, R H It is -H1-H2-NR2R3; Wherein, H1 is selected from chemical bonds, -O-, -S-, -NR1-, -C(O)-, -S(O)- and -S(O)2-; preferably chemical bonds, -O-, -S- and -NR1-; preferably chemical bonds, -O- and -NR1-; preferably chemical bonds and -NR1-; preferably -NR1-; H2 is -(CH2) a - wherein one, two or three methylene units are optionally and independently replaced by -O-, -S- or -NR1- (preferably -O-); a = 1, 2, 3, 4, 5 or 6, preferably a = 1, 2, 3 or 4, preferably a = 1 or 2, preferably a = 2; R1 is independently selected from H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups, preferably H or C 1-4 Alkyl or C 1-4 Haloalkyl, preferably H; R2 and R3 are each independently selected from H and C. 1-6 Alkyl, C 1-6 The alkyl halogroup and the hydrophilic group of polyhydroxy alcohol, preferably H and the hydrophilic group of polyhydroxy alcohol, and at least one of R2 and R3 is a hydrophilic group of polyhydroxy alcohol; Preferably, The hydrophilic group of the polyhydroxy alcohol has the following structure: -X1(CR7OH)zX2R8; Among them, X1 and X2 are independently selected from chemical bonds, C 1-6 Alkylene, -NR1-, -C(O)-, -S(O)- and -S(O)2-, preferably chemical bonds, C 1-6 Alkylene (preferably C) 1-4 Alkylene, preferably C 1-2 -alkylene), -NR1- and -C(O)-, preferably C 1- 4-alkylene group, preferably C 1-2 Alkyl groups, such as methylene groups; R7 is independently selected from H and C. 1-6 Alkyl or C 1-6 Halogenated alkyl groups; preferably H or C 1-4 Alkyl or C 1-4 Halogenated alkyl; preferably H; R8 is independently selected from H, CN, and -OR. a -NR b R c C 1-6 Alkyl or C 1-6 Halogenated alkyl groups, preferably H or -OR a C 1-6 Alkyl or C 1-6 Halogenated alkyl groups, preferably -OR a Preferred -OH; z is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 3, 4, 5 or 6; Preferably, The polyhydroxy alcohol hydrophilic group is selected from... (Preferred) )and (Preferred) )。 9. A compound of formula (I) according to any one of claims 1-8, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, R4 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl, C 1-6 Halogenated alkyl groups, polyethylene glycol, polysarcosine, pentose sugars, hexose sugars, sulfonic acid groups, methanesulfonyl groups, phosphoric acid groups, phosphite groups, quaternary ammonium salts, or groups selected from the following: Preferably, R4 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

10. A compound of formula (I) according to any one of claims 1-9, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, L3 is selected from chemical bonds or the following structures: Preferred chemical bonds or Preferred chemical bonds or Preferably, R5 is independently selected from H, D, halogen, C. 1-6 Alkyl and C 1-6 Halogenated alkyl groups; Preferably, R6 is selected from H, H is preferred.

11. A compound of formula (I) according to any one of claims 1-10, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, D is selected from cytotoxins, antitumor drugs, anti-infective drugs, or immunomodulatory drugs; Preferably, D is a cytotoxic agent, such as a tubulin inhibitor, topoisomerase inhibitor, DNA alkylating agent, DNA chimera, enzyme inhibitor, immunomodulator, PROTAC, antimetabolite, bioactive peptide, or bioactive nucleotide sequence. Preferably, D is selected from microtubule inhibitors, DNA topoisomerase inhibitors, drugs that interfere with DNA synthesis, DNA alkylating agents, DNA chimeras, enzyme inhibitors, RNA inhibitors, Bcl-xL inhibitors, NAMPT inhibitors, proteasome inhibitors, carbamycin, immunomodulators, PROTAC, antimetabolites, bioactive peptides, nucleotides, tumor signaling pathway inhibitors, histone deacetylase inhibitors, tumor angiogenesis inhibitors, cyclin inhibitors, drugs that act on structural proteins, metal complexes, or glycopeptide antibiotics. Preferably, D is a cytotoxic substance, preferably selected from maytansine and its derivatives, olistatin and its derivatives, tubulysins and its derivatives, tubulin and its derivatives, cryptophytin and its derivatives, eribulin and its derivatives, pyrrolobenzodiazepines (PBDs) and their derivatives, enediyne molecules and their derivatives, pyroxine and its derivatives, and other active substances that inhibit tumor cell growth and promote tumor cell apoptosis or necrosis. Preferably, D is selected from olistatin and its derivatives, camptothecin and its derivatives, maytansine and its derivatives, calcimycin and its derivatives, paclitaxel and its derivatives, pyrrolobenzodiazepines and their derivatives, pyroxine, doxorubicin, melphalan, mitomycin C, chlorambucil, and other active substances that inhibit tumor cell growth and promote tumor cell apoptosis or necrosis. Preferably, D is selected from monomethylorlistatine E (MMAE), monomethylorlistatine F (MMAF), DM1, DM4, Dxd (CAS: 1599440-33-1), ixotecan (Dx-8951f), oxaliplatin, bleomycin, bleomycin, camptothecin, hydroxycamptothecin, 9-aminocamptothecin, SN-38, irinotecan, topotecan, belotetan, rubotecan, and actinomycin. D. Doxorubicin, Docalimicin, Daunorubicin, Mitoxantrone, Podophyllotoxin, Etoposide, Methotrexate, 5-Fluorouracil, Cytarabine, Gemcitabine, Mercaptopurine, Pentostatin, Fludarabine, Clardribine, Nerapine, Vincristine, Vincristine, Paclitaxel, Docetaxel, Cabazitaxel, Serine / Threonine kinase inhibitors, Tyrosine kinase inhibitors, Aspartate kinase inhibitors, or Histidine kinase inhibitors; Preferably, D is selected from microtubule inhibitors, topoisomerase I inhibitors, and DNA alkylating agents, such as MMAE, MMAF, Dxd, or Dx-8951f, with MMAE or Dx-8951f being more preferred.

12. A compound of formula (I) according to any one of claims 1-11, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, having the following general formula: in, b = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably b = 0, 1, 2, 3, 4, 5 or 6, preferably b = 0, 1, 2 or 3, preferably b = 2; The remaining variables are defined as described in any one of claims 1-11.

13. The compound of formula (I) of claim 12, or its prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, having the structure of formula (I-1): in, *1 is a chiral center, independently selected from the (S) or (R) configuration, or a racemic form; the (S) configuration is preferred; U is selected from W1 is -W 1a -W 1b -; W 1a Selected from chemical bonds or -(CH2) m24 -; Preferred chemical bonds; W 1b Selected from -C(O)O- or -C(O)NH-; preferably -C(O)NH-; m24 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; preferably 1, 2, 3, 4, 5 or 6; L1 is selected from -(CH2CH2O) n11 -(CH2) m11 -or-(CH2) m21 -; Where n11 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; m11 = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; m21 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; W2 is -C(O)-; a = 1, 2, 3, 4, 5 or 6, preferably a = 1, 2, 3 or 4, preferably a = 1 or 2, preferably a = 2; b = 0, 1, 2, 3, 4, 5 or 6, preferably b = 0, 1, 2 or 3, preferably b = 2; R2 and R3 are each independently selected from H and C. 1-6 Alkyl, C 1-6 The alkyl halogroup and the hydrophilic group of polyhydroxy alcohol, preferably H and the hydrophilic group of polyhydroxy alcohol, and at least one of R2 and R3 is a hydrophilic group of polyhydroxy alcohol; The polyhydroxy alcohol hydrophilic group is selected from... (Preferred) )and (Preferred) ); AA1 is selected from the following amino acid residues or oligopeptide residues consisting of 2-3 (preferably 2) or fewer amino acids; wherein the amino acid is selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably valine, alanine, leucine, and isoleucine, preferably valine and alanine, and preferably valine-alanine; and wherein the amino acid is optionally substituted by 1, 2, 3, 4, 5, or 6 R4 residues; The N-terminus of the amino acid residue or oligopeptide residue is linked to -C(O)-, and the C-terminus is linked to L3; R4 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl and C 1-6 Halogenated alkyl groups; L3 is a chemical bond or Preferred chemical bonds or NH is connected to L2, and C(O) is connected to D; R5 is independently selected from H, D, halogen, and C. 1-6 Alkyl and C 1-6 Halogenated alkyl groups; t = 0, 1, 2, 3 or 4; D is selected from microtubule inhibitors, topoisomerase I inhibitors, and DNA alkylating agents, such as MMAE, MMAF, Dxd, or Dx-8951f, preferably MMAE or Dx-8951f.

14. The compound of claim 12, or its prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, having the structure of formula (I-2): in, *2 is a chiral center, independently selected from the (S) or (R) configuration, or a racemic form; the (S) configuration is preferred; U is selected from W1 is -W 1a -W 1b -; W 1a Selected from chemical bonds or -(CH2) m24 -; Preferred chemical bonds; W 1b Selected from -C(O)O- or -C(O)NH-; preferably -C(O)NH-; m24 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; preferably 1, 2, 3, 4, 5 or 6; L1 is selected from -(CH2CH2O) n11 -(CH2) m11 -or-(CH2) m21 -; Where n11 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; m11 = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; m21 = 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; W2 is -C(O)-; AA2 is selected from the following amino acid residues or oligopeptide residues consisting of 2-3 or fewer amino acids; wherein the amino acids are selected from cysteine, phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably the following amino acid residues: valine, alanine, leucine, and isoleucine, with valine being the most preferred; and wherein the amino acids are optionally substituted by 1, 2, 3, 4, 5, or 6 R4 residues; The N-terminus of the amino acid residue or oligopeptide residue is linked to W2, and the C-terminus is linked to -NH-. R4 is independently selected from H, D, halogens, NO2, and -OR. a -NR b R c C 1-6 Alkyl and C 1-6 Halogenated alkyl groups; a = 1, 2, 3, 4, 5 or 6, preferably a = 1, 2, 3 or 4, preferably a = 1 or 2, preferably a = 2; b = 0, 1, 2, 3, 4, 5 or 6, preferably b = 0, 1, 2 or 3, preferably b = 2; R2 and R3 are each independently selected from H and C. 1-6 Alkyl, C 1-6 The alkyl halogroup and the hydrophilic group of polyhydroxy alcohol, preferably H and the hydrophilic group of polyhydroxy alcohol, and at least one of R2 and R3 is a hydrophilic group of polyhydroxy alcohol; The polyhydroxy alcohol hydrophilic group is selected from... (Preferred) )and (Preferred) ); L3 is a chemical bond or Preferred chemical bonds or Preferred chemical bonds; NH is connected to L2, and C(O) is connected to D; R5 is independently selected from H, D, halogen, and C. 1-6 Alkyl and C 1-6 Halogenated alkyl groups; t = 0, 1, 2, 3 or 4; D is selected from microtubule inhibitors, topoisomerase I inhibitors, and DNA alkylating agents, such as MMAE, MMAF, Dxd, or Dx-8951f, preferably MMAE or Dx-8951f.

15. A compound of any one of claims 1-14, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from:

16. A compound of formula (II), or its prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof: in, A is a targeted molecule; U' is a group formed after the reaction of the linker and the thiol group; x = 1, 2, 3, 4, 5, 6, 7 or 8; The remaining variables are defined as described in any one of claims 1-14.

17. The compound of claim 16, or its prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, A is selected from proteins, antibodies, nanobodies, bispecific antibodies, antibody fragments, fusion proteins, peptides, enzymes, and small molecules; A is preferably an antibody, preferably a monoclonal antibody, such as a monospecific monoclonal antibody and a bispecific monoclonal antibody; A is preferably an IgG antibody targeting tumor-associated antigens.

18. The compound of claim 16 or 17, or its prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, A represents an antibody that targets tumor-associated antigens including, but not limited to: HER2, Trop-2, Claudin-6, Claudin-9, Claudin-18.2, EGFR, c-Met, CD19, PSMA, Muc1, BCMA, PD-L1, CD33, CD30, CD22, CD79b, Nectin-4, CD19, tissue factor, FRα, B7-H3, B7-H4, CDH3, CDH6, CDH17, CD56, CD37, HER3, ROR1, MSLN, TNF-α, and CD25. ENPP3, Muc1, Axl, CD20, ROR2, GPNMB, CEACAM5, CEACAM6, EPHA5, TL1A, CD138, GC-C, LIV-1, CA6, FUT3, IGF-1R, CTLA4, RNF43, DPEP 3. 5T4, ITGB6, EFNA4, CD228, Notch3, CD46, CAIX, SLAMF6, ADAM9, GD3, TDGF1, SLAMF2, CLL-1, CD123, FCRL5, TIM1, sTn, ETB, Globo H, CD38, Ly6E, SLITRK6, GPR20, FGFR2, FGFR2b, Muc16, CD5 1. SLAMF7, LAMP-1, CD74, CCR7, PTK7, SEZ6, LYFD3, TAA, PRL receptor, FGFR3, KAAG1, STEAP1, Flt3, Muc1, LRRC15, CD44, CD70, EphA2, CXCR4, DDR1, DKL1, FOLR, CD45, DSG2, ALK, TRAIL, EpCAM, VEGFR2, CD47, CD49, SS EA-4, DCLK1, OacGD2, CD73, EN01, BSG, CD24, GLUT1 and GPRC5D, preferably HER2, HER3, EGFR, Trop-2, Claudin-6, Claudin-18.2, B7-H3, B7-H4, CDH3, CDH6, CDH17, FRα, ROR1, ALPP, CEACAM5, CEACAM6, EPHA5, TL1A or FOLR.

19. A compound of any one of claims 16-18, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, U' is selected from: Preferred Preferred The carbon atom at the # end is linked to the sulfur atom in the cysteine ​​residue of the targeted molecule A through a thioether bond.

20. The compound of any one of claims 16-18, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein, x = 2, 3, 4, 5, 6, 7 or 8, preferably x = 2, 4, 6 or 8, more preferably x = 4, 6 or 8, and even more preferably x = 4 or 8.

21. A compound of any one of claims 16-20, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, having the following general formula: Each variable is defined as described in any one of claims 1-19.

22. A compound of any one of claims 16-21, or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic mixture, or tautomer, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from: in, The antibody is indicated; preferably a monoclonal antibody or a bispecific antibody; preferably an IgG1 type monoclonal antibody; more preferably an IgG1 type monoclonal antibody against HER2 and CDH76.

23. A pharmaceutical composition comprising a compound of any one of claims 16-22 or a prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic or tautomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or excipient.

24. Use of any compound of claims 16-22 or its prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic or tautomer, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 23, in the preparation of a medicament for treating a disease or condition and for reducing the severity of said disease or condition.

25. The compound of any one of claims 16-22 or its prodrug, hydrate, solvate, enantiomer, diastereomer, meso compound, racemic compound or tautomer, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 23, for the treatment of a disease or symptom and for the relief of the severity of said disease or symptom.

26. A method of treating a disease or condition in a subject and reducing the severity of said disease or condition, comprising administering to the subject a compound of any one of claims 16-22 or a prodrug thereof, a hydrate, a solvate, an enantiomer, a diastereomer, a meso compound, a racemic compound or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 23.

27. The use of claim 24, or the compound or pharmaceutical composition of claim 25, or the method of claim 26, wherein the disease or condition is selected from tumors, cancer, autoimmune diseases, infectious diseases, hematological diseases, metabolic diseases, and inflammation; Preferably, the cancer is selected from breast cancer, lung cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, stomach cancer, esophageal cancer, gastrointestinal cancer, endometrial adenocarcinoma, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, urethral cancer, intestinal cancer, uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, penile cancer, thyroid cancer, anal cancer, melanoma, brain cancer, gallbladder cancer, esophageal cancer, bile duct cancer, head and neck cancer, lymphoma, multiple myeloma, blastoma, leukemia, myeloma, plasmacytoma, sarcoma, and pancreatic cancer, mesothelioma, and nasopharyngeal carcinoma.